EHA Unplugged: Recent Episodes
European Hematology Association
In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.
In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research.
From his early interest in fibrinolysis during medical school to his current role as Chair of the Department of Hematology at Erasmus Medical Center and Board member at EHA, Prof. Leebeek shares how a dual commitment to research and patient care has shaped his path.
The conversation explores key milestones in bleeding disorders research, including large-scale studies on von Willebrand disease that helped improve awareness, diagnosis, and patient-reported outcomes. Prof. Leebeek also discusses his involvement in pioneering gene therapy trials for hemophilia, which have transformed treatment paradigms and patients’ quality of life, while noting ongoing challenges in access and affordability. Beyond research, he reflects on the importance of collaboration, the value of long-term patient relationships, and the role of European-level initiatives in advancing hematology care.
Tune in to hear insights from a leading figure in benign hematology and learn how sustained collaboration and innovation continue to drive progress in the field.
Guest: Prof Frank Leebeek
Affiliation: Erasmus Medical Center, Rotterdam, The Netherlands
Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRTH) program helped shape his path.
Prof. Mai reflects on the practical and often underappreciated challenges of clinical trial design—from budgeting and statistical planning to ethical considerations and regulatory requirements. He highlights the importance of mentorship and peer networks, as well as the need for persistence when ideas are ahead of their time. The conversation also explores the skills hematologists need to get started in clinical research, with a clear message: developing trials is a multifaceted process that requires both scientific expertise and hands-on learning.
Whether you are early in your career or considering a move into clinical research, this episode offers valuable insights into how to take the first steps, overcome challenges, and ultimately contribute to improving patient care through clinical trials.
Guests:
Prof Elias K. Mai
Heidelberg University Hospital, Heidelberg, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma.
The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The experts discuss the integration of novel prognostic tools such as minimal residual disease (MRD), circulating tumour cells and mass spectrometry, and their evolving role in risk stratification.
The episode also reviews key recommendations for frontline management and provides practical guidance for selecting therapies in relapsed and refractory multiple myeloma. Throughout the discussion, the speakers highlight how the updated guidelines support clinicians in navigating an increasingly complex therapeutic landscape.
Guests:
Prof. Meletios Dimopoulos and Prof. Evangelos Terpos
National and Kapodistrian University of Athens, Greece
Host: Prof. Pieter Sonneveld
Erasmus University Medical Center, Rotterdam, The Netherlands
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.
In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities.
Guests:
Dr Paula Rodríguez-Otero
Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation.
In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes.
Guests:
Dr Scott Armstrong
Dana-Farber Cancer Institute
Prof Marc Raaijmakers
Erasmus Medical Center
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas.
In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments.
This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more.
Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations.
Link to the guideline: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - Hübel - 2024 - HemaSphere - Wiley Online Library
Guest: Prof Kai Hübel
Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia.
Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes she’d known at the very beginning of her journey.
Guest: Associate Prof Meritxell Alberich Jordà
Institute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library).
Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines, walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up.
Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond.
Guests: Prof Catherine Thieblemont and Prof Marie José Kersten.
Professor Catherine Thieblemont from Saint-Louis Hospital in Paris.
Professor Marie José Kersten from Amsterdam University Medical Centers (UMC)
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies.
Guest: Peter Kapitein
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Guest: Peter Kapitein
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy).
In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas.
Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from “one size fits all” DLBCL style approach toward entity- adapted strategies.
Throughout the conversation, they stress the need to read the full guideline – including the supplementary material – and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy.
GuestS: Prof Francesco D'Amore and Prof Massimo Federico.
Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark
Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in Italy
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join EHA President Prof Konstanze Döhner from University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics.
Listen as Prof. Döhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator. Tune in to hear Prof. Döhner describe her journey to becoming the EHA president and her reflections on the current challenges in the hematology field and the solutions she proposes to address those.
Guest: Prof Konstanze Döhner, University Hospital Ulm, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammation‑driven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributing to clonal hematopoiesis.
Learn about the mechanisms of blood cells aging andpotential interventions to slow down the process.
Guest: Dr Michael Milsom
Head of the Division of Experimental Hematology at the German Cancer Research Center, (DKFZ), and group leader at the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‑STEM), Heidelberg, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) with Prof Mats Jerkeman (Lund University, Sweden).
In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including the expanding role of BTK inhibitors (such as ibrutinib) in first-line regimens.
He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy have largely supplanted but not fully replaced allogeneic transplantation.
Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges.
Link to the guideline: (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library)
Link to Lund University:
Mats Jerkeman - Lund University
Home | Lund University
Learn More
Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma.
Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission.
Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions.
Host: Dr Sarah de Vlieger
Guest: Jonathan Clark
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024.
Learn More
Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.
Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction.
The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't."
Host: Dr Wilson Lim
Guest: Dr Gregor Hormann
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
[This is a Rerelease. Episode first published on November 1, 2024.]
Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future.
The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint.
Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.
Host: Dr Sarah de Vlieger
Guest: Dr Stephen Hibbs
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
[This is a Rerelease. Episode first published on April 11, 2025.]
Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field.
Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design.
Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies.
If you want to know more:
https://www.nature.com/articles/s41746-024-01076-x
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Dr. Jan Moritz Middeke
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this interview with Dr Río-Machín from Autonomous University of Madrid in Spain as she discusses her research on rare subtypes of acute myeloid leukemia (AML), which she conducted thanks to the EHA Junior Research Grant.
Her discovery of transcriptional activator of key leukemia drivers in one of these subtypes may pave way to new therapeutic approaches.
Tune in to hear dr. Río-Machín‘s call for more collaborative research to achieve impactful results for patients in the future.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Dr Ana Río-Machín
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this discussion between Prof Argiris Symeonidis from University of Patras in Greece and Prof Sam Salek from University of Hertfordshire in UK who focus on the role of the hematologist in the diagnosis and management of patients with Gaucher disease.
Prof Symeonidis and Prof Salek are both experts in recognizing and treating this rare lysosomal storage disorder and share their recommendations for hematologists to ensure earlier detection of this disease.
Host: Prof. Sam Salek, University of Hertfordshire, UK
Guest: Prof. Argiris Symeonidis, University of Patras, Rion, Greece
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this inspiring interview with Erik Aerts from University Hospital Zurich in Switzerland and Mairéad Ní Chonghaile from St. James’s Hospital in Ireland who discuss their extensive work within the Hematology Nurses & Healthcare Professionals Group (HNHCP).
Erik, the President, and Mairéad, the Vice-President of HNHCP, describe their unwavering commitment to providing hematology education to nurses and other healthcare professionals to ensure the best possible care for their patients. Tune in to hear what their thoughts are on the future of nursing in hematology and how they envisage addressing its biggest challenges.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guests:
Erik Aerts, Nurse Manager, University Hospital Zurich, Switzerland and President of Hematology Nurses & Healthcare Professionals Group (HNHCP)
Mairéad Ní Chonghaile, Bone Marrow Transplant Coordinator, St. James’s Hospital, Dublin, Ireland and Vice-President of HNHCP
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this inspiring interview with prof. Jesús San-Miguel from Clínica Universidad de Navarra in Spain who discusses his extensive work to improve care for patients with multiple myeloma.
Prof San-Miguel’s research and clinical contributions have shaped the current treatment landscape for multiple myeloma.
For his contributions, he has received the 2025 EHA Lifetime Achievement Award. Tune in to hear his thoughts about the future of multiple myeloma management and the crucial role that collaborative research will play in it.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Jesús San-Miguel, Clínica Universidad de Navarra, Spain
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this interview with Dr Mandy Lauw from Erasmus Medical Center in Rotterdam, Netherlands who describes her work to increase the visibility and voice of young hematologists within the EHA.
For her unwavering efforts to improve the support and opportunities for young hematologists at the beginning of their career, Dr Lauw has been awarded the Young EHA Award.
Tune in to hear about the many educational and mentoring programs EHA has available for young hematologists.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Dr Mandy Lauw
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this interview with Dr Ferran Nadeu Prat from August Pi i Sunyer Biomedical Research Institute in Barcelona, Spain who discusses his work on evolution of chronic lymphocytic leukemia (CLL), which he conducted thanks to the EHA Junior Research Grant.
Dr Nadeu Prat explains how the new insights into CLL evolution toward Richter transformation, which is a lethal complication of CLL, may lead to new therapeutic approaches.
Tune in to hear his views on the future of this field and the role of collaborative research in achieving these goals.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Dr Ferran Nadeu Prat, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this conversation with prof. Mariane de Montalembert from Necker-Enfants Malades Hospital in France who discusses the current standards of care for patients with sickle cell disease and thalassemia, both in Europe and in sub-Saharan Africa.
Prof. de Montalembert highlights the inequalities and the unique challenges in implementation of complex innovative treatments, such as gene therapy.
Tune in to hear her thoughts on the possible solutions for these challenges and future directions in this field.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Mariane de Montalembert, Necker-Enfants Malades Hospital, Paris, France
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this inspiring interview with prof Béatrice Gulbis from The Brussels University Hospital in Belgium who discusses her extensive work on implementing neonatal screening for sickle cell disease (SCD) in low-resource countries in Africa.
Prof Gulbis has been involved in collaborative projects to implement the testing methods that best fit the specific contexts. Tune in to hear her recommendations for the optimal SCD screening systems and her hopes for the worldwide collaborative approach to improve care for patients with SCD.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Béatrice Gulbis, The Brussels University Hospital, Belgium
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this interview with dr. Côme Bommier from Saint-Louis Hospital in Paris, France who describes the results of the recent EHA survey on burnout symptoms among hematology professionals in Europe.
Dr. Bommier discusses the findings of the survey in the context of modifiable systemic factors. Tune in to hear him urge organizational reforms to ensure better work environments for hematologists, leading ultimately to better outcomes for patients.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Dr. Côme Bommier, Saint-Louis Hospital, Paris, France
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this inspiring conversation with prof. Anna Schuh from University of Oxford in the United Kingdom who describes her efforts to improve access to care for patients with hematological diseases in East African countries.
Prof. Schuh describes the experience of sharing her time between the UK and East Africa and how this has impacted her clinical practice in both environments. Tune in to hear what her views are on how the Global North and Global South can learn from each other to improve care for patients everywhere.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Anna Schuh, University of Oxford, United Kingdom
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this inspirational interview with prof. Jan Cools from KU Leuven in Belgium who received the EHA 2025 Education & Mentoring Award.
Prof. Cools describes his approach to mentoring students and scientists, emphasizing the aspects that he finds most crucial in this role. Tune in to hear his thoughts about the future of mentoring, the place artificial intelligence may take in it and the importance of failure on the road to success.
Host: Isabel Olivera-Martinez, PhD, Medical Writer, EHA
Guest: Prof. Jan Cools, KU Leuven Department of Human Genetics, Belgium
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, we sit down with prof. Khaled Musallam from Burjeel Medical City in United Arab Emirates who discusses his extensive work to improve care for patients with thalassemia.
Prof. Musallam’s research and clinical contributions have reshaped the management of both non-transfusion-dependent thalassemia (NTDT) and transfusion-dependent thalassemia (TDT). Tune in to hear his views on the current practice and future directions in the prevention and treatment of morbidities associated with thalassemia.
For a comprehensive review of all aspects of thalassemia, the EHA Thalassemia Program is available to all EHA Members on Campus.
Stay tuned for future episodes!
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Khaled Musallam
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this discussion between Robin Doeswijk, EHA European Affairs and prof. John Gribben from Barts Cancer Institute in the United Kingdom on the topic of equity in care of patients with hematologic malignancies.
This discussion follows the recently published “European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological Malignancies”. Tune in to hear how this combination of organizational guidelines and clinical practice recommendations aims to improve diagnosis and care for all patients across Europe.
Host: Robin Doeswijk, EHA European Affairs
Guest: Prof John Gribben
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this captivating interview with Prof Kirsten Grønbæk from University of Copenhagen in Denmark, as she discusses her outstanding career in the field of hematology, both in research and in the clinics.
Listen to how the interests of Prof Grønbæk evolved, leading her from the initial focus on epigenetics in lymphomas to MDS in the later years of her career.
Prof Grønbæk reflects on the current developments in MDS and her tips for the leading a successful research team in hematology.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Kirsten Grønbæk
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, we sit down with Prof. Maria Domenica Cappellini from the University of Milan in Italy, as she discusses her inspiring career as a hematologist specializing in the management of patients with thalassemia.
Listen to the compelling story of how Prof. Cappellini’s interest in thalassemia started and how her relentless stride for the best possible care for her patients has helped to transform the way this disease is managed.
Tune in to hear prof. Cappellini’s words of advice for the younger generation of hematologists interested in the field of thalassemia.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Maria Domenica Cappellini
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Explore the latest breakthroughs in gene therapy for sickle cell disease and beta thalassemia with Dr. Stefano Rivella, hematologist and research faculty at Children's Hospital of Philadelphia.
In this episode, Dr. Rivella discusses the science behind FDA-approved therapies, compares gene addition and gene editing approaches, and shares insights on clinical safety, efficacy, and future innovations like in vivo gene therapy.
Learn about the challenges of access, cost, and global equity, and discover how evolving technologies could transform treatment for patients worldwide.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Dr Stefano Rivella
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this insightful interview with prof. Hartmut Döhner from University Hospital Ulm in Germany who tells about most recent developments in the management of older and unfit patients with AML.
Prof. Döhner discusses all key aspects of the management including assessing patient fitness, genetic risk classification, and the choice of treatment, among which also the emerging therapies.
Tune in, to hear about the most relevant recommendations for the clinical decision making while treating older unfit patients with AML.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Hartmut Döhner, University Hospital Ulm, Germany
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join EHA President prof. Konstanze Döhner from University Hospital Ulm in Germany who discusses the most recent developments in the management of young and fit patients with AML. Tune in to hear about the diagnostic workup, risk stratification, treatment and the evolving role of measurable residual disease (MRD) measurements in clinical decision making in this group of patients. Prof. Döhner also shares her thoughts on the future of the treatment landscape for AML.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Konstanze Döhner
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as Prof. Christian Chabannon from Aix Marseille Université in France who tells about GoCART Coalition in this new podcast episode. The main goal of this coalition, which unites expertise from many fields, is to promote access to novel cellular therapies, such as CAR T-cells. Prof. Chabannon explain how GoCART is working on reaching this goal by generating new clinical insights, improving standards of care, providing education and building policy. Tune in to learn more about the impact of this coalition on healthcare today and in the future.
Stay tuned for future episodes!
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof. Christian Chabannon
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Jan Geissler from Germany tells about his work as a patient advocate in the field of hematological malignancies. As a cancer survivor, patient advocate and patient engagement expert, Jan has been working tirelessly for many years in organizations such as European Patients Academy (EUPATI), Patvocates and many others. Listen to Jan’s passionate call for a collaborative spirit to achieve the best outcomes for patients. Tune in to hear his views on patient advocacy and the impact it has on patient care.
Stay tuned for future episodes!
Guest:Jan Geissler, Patient Advocate, Germany
Host:Isabel Olivera-Martinez, PhD, Medical Writer
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Prof. Maria Themeli tells about most recent developments in the field of “off-the-shelf” CAR T-cells. As the clinical success of advanced cellular therapies is growing, so is the need for broader access to these treatments. Listen as Prof. Themeli summarize the state-of-the-art technology that aims to generate “off-the-shelf” CAR T-cells from sources such as induced pluripotent stem cells (iPSCs) and how this approach may offer a feasible strategy to improve clinical outcomes and reduce the costs of advanced cellular therapies in the future.
Stay tuned for future episodes!
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Maria Themeli
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join dr. Carmen Sanges from University Clinic Würzburg in Germany as she tells us about AIDPATH. This collaborative initiative is dedicated to improving access to advanced cellular therapies by employing artificial intelligence (AI) in the production process. Listen to dr. Sanges explain how AI technology is used to integrate patient-specific information and biomarkers to optimize CAR-T therapy. Tune in to hear about the current approaches and future directions of this cutting-edge technology.
Stay tuned for future episodes!
Host: Isabel Olivera-Martinez, Medical Writer
Guest: Dr Carmen Sanges
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this inspiring interview with prof. Elizabeth Macintyre from Université Paris Cité in France who tells us about her professional journey in hematology.
Listen to prof. Macintyre discuss her views on the current state and future directions of advanced diagnostics in malignant hematology and their implications for healthcare management and the training of young specialists. Tune in to hear how Biomedical Alliance may impact future policies through “trans-European” approaches.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Elizabeth Macintyre
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join Professor Kirsten Gronbaek and Professor Uwe Platzbecker as they discuss the complexities behind the classification and prognostication of low-risk myelodysplastic syndromes (MDS). They dive into the historical context of MDS classification, the evolution of prognostic indexes such as IPSS and IPSSM, and the implications of recent molecular findings.
This conversation highlights the challenges in defining "low-risk" MDS, the role of genetic mutations in prognosis, and the considerations for treatment strategies, including the potential for stem cell transplantation.
Host: Professor Kirsten Gronbaek, University of Copenhagen, Denmark
Guest: Professor Uwe Platzbecker, University Clinic of Leipzig
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join host Professor Kirsten Gronbaek and guest Professor Arjan van de Loosdrecht as they dive into the complexities of measurable residual disease (MRD) monitoring in myelodysplastic syndromes (MDS) and myeloid cancers. Professor van de Loosdrecht explains the transition from minimal to measurable residual disease, the significance of MRD in predicting disease outcomes, and the various techniques used for MRD detection.
Listen as they explore the challenges and potential strategies for MRD monitoring in MDS, and the implications for treatment decisions. This episode is a must-listen for anyone interested in the latest advancements in hematology and the future of MRD monitoring in MDS.
Tune in to EHA Unplugged to gain valuable insights and stay updated with the latest research and clinical practices in hematology.
Host: Prof Kirsten Gronbaek
Guest: Prof Arjan van de Loosdrecht
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, we sit down with prof. Martin Dreyling from the Ludwig-Maximilians-University in Munich who talks about his professional journey in hematology as a clinician and a researcher.
Listen to prof. Dreyling as he recalls his contributions to the field of lymphoma, and in particular mantle cell lymphoma, that resulted in novel therapeutic approaches. The ongoing emphasis on the cross-border teamwork in clinical trials and the importance of European cooperation highlights the impact that these initiatives had on prof. Dreyling’s career.
Tune in to hear his thoughts about the future directions in lymphoma treatment and collaborative clinical research in general.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: prof. Martin Dreyling
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, prof. Kirsten Gronbaek and dr. Shahram Kordasti discuss the role of immune dysfunction in MDS. With the improving understanding of complex pathophysiology of MDS, the major role of the immune system in this process is becoming increasingly apparent.
Listen to dr. Kordasti discuss the multifactorial interactions between the malignant clones and the inflammatory environment, manifesting in elements of autoimmunity and elements of autoinflammation in MDS. As the complexity of immunophenotypes observed in MDS is being unraveled, the need to include immunophenotypic factors in the prognostic scores is growing.
Tune in to hear dr. Kordasti’s and prof. Gronbaek’s thoughts on the future of prognostication, the more comprehensive approach for patient stratification designed to predict therapy responses and the future of immunotherapy in MDS.
Host: Prof Kirsten Gronbaek
Guest: Dr Shahram Kordasti
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this interview, dr. Maria del Mar Mañu Pereira from Vall d’Hebron Research Institute in Spain talks about the Rare Anemia Disorders European Epidemiological Platform (RADeep). RADeep is an initiative of ERN-EuroBloodNet and functions as an umbrella for both new and already existing European patients' registries in rare anemia disorders.
Listen to dr. Mañu Pereira talk about the history of RADeep from its early days until today and about its ambitious goals to advance research and promote best practices in care for RAD patients across Europe. You will hear about the milestones achieved, current research, and how RADeep registry and the ENROL (European Rare Blood Disorders Platform) initiative complement each other to achieve optimal health outcomes for RAD patients.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Dr. Maria del Mar Mañu Pereira
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Prof. Antonio Almeida from Hospital da Luz in Lisbon takes us through his professional journey in hematology as a clinician and educator, and his current role as the President of EHA. Listen to prof. Almeida recount his professional path that allowed him to experience various facets of hematological clinical practice in the UK and Portugal.
Alongside his career as a hematologist, prof. Almeida cultivated a growing love for education, where he tries to employ student-centered techniques to enhance educational experiences.
Tune in to hear how prof. Almeida describes his journey to becoming the President of EHA and what he sees as today’s most significant challenges in hematology and what solutions he has in mind to address those.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof. Antonio Almeida
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for a conversation between prof. Kirsten Gronbaek and her guest prof. Dominik Wolf, as they discuss targeting the immune system in MDS management. In light of accumulating evidence that inflammatory signals play a role throughout disease evolution in MDS patients, prof. Wolf elucidates the current insights and possible future therapeutic options.
He uses the example of targeting NLRP3/IL-1 axis in low-risk MDS to highlight the need of understanding the underlying cellular biology to translate that knowledge into clinical approaches. He also discusses the concept of possibly targeting both non-clonal and clonal compartments for better patient outcomes in the future.
Tune in, to hear about other future directions in treatment of MDS, such as recent developments in CAR T-cell approaches and about the central role that allo-transplantation is likely to keep in the treatment of high-risk MDS. You will also hear about the potential link between inflammation and fatigue, which is clinically highly relevant, but as yet an unsolved issue in MDS.
Host: prof. Kirsten Gronbaek
Guest: prof. Dominik Wolf
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design.
Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies.
If you want to know more:
https://www.nature.com/articles/s41746-024-01076-x
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Dr. Jan Moritz Middeke
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, Dr. Onima Chowdhury, a hematologist from the University Hospital in Oxford, talks about the diagnostic workup of Myelodysplastic Syndromes (MDS). With a focus on both clinical practice and research, Dr. Chowdhury outlines the essential steps and tests required for diagnosing MDS, discusses the role of morphology, cytogenetics, and the significance of NGS panels in the diagnostic process.
The conversation also touches on the potential of artificial intelligence in diagnostics, the prognostic value of genetic mutations, and the importance of considering germline disorders in MDS. This episode is a must-listen for healthcare professionals seeking to deepen their understanding of MDS diagnostics.
Host: Prof Kirsten Grønbæk
Guest: Dr Onima Chowdhury
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this insightful interview with prof. Brian Huntly from the University of Cambridge who tells about his professional journey in hematology as a clinician, scientist and educator.
Listen to prof. Huntly discuss his important contributions to the field of leukemia stem cell biology in the context of current understanding of cell biological hierarchies and leukemia development.
Prof. Huntly also touches on the concepts of early interception and tumor-specific and tumor-nonspecific areas to personalized medicine. Tune in to hear how prof. Huntly combines his work in the fields of science and clinical medicine and what his recommendations are for younger colleagues, who are in the early stages of their careers.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Brian Huntly
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, Prof Dame Lesley Fallowfield and Prof Clemens Wendtner discuss patient mental health and communication in the context of Chronic Lymphocytic Leukemia (CLL) treatment. They explore the psychological impact of CLL and leukemia in general, the importance of patient communication, and the need for integrated mental health support.
The conversation highlights the challenges of explaining complex medical concepts to patients and the role of resilience in both patients and physicians. They also address the challenges of managing patient anxiety and depression, the role of trust in the doctor-patient relationship, the importance of empathy, and the need for integrated psychological support services.
Guests:
Prof Dame Lesley Fallowfield
Prof Clemens Wendtner
Note: This podcast is based on content provided by BeiGene. It has been reviewed by EHA, which found it unbiased and aligned with EHA educational standards, as well as edited by EHA to create an effective educational experience.
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an insightful interview with patient advocates Miriam Santos Freire (sickle cell disease) and Loris Brunetta (beta-thalassemia major). Benefit from their experiences as they discuss with our host Isabel Olivera-Martinez the promises and challenges of gene therapy for these conditions.
Listen to their experiences of living with these genetic conditions while they highlight the disparities in treatment access between wealthy and low-income countries. Both view gene therapy as a breakthrough that has the potential to cure these diseases, but express caution regarding its current limitations and complications. Tune in for their valuable insights and recommendations for advancing SCD and thalassemia management.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guests:
Miriam Santos Freire, Patient representative for EuroBloodNet
Patient Advocacy & Communication for Sickle Cell (Portugal & UK) at European Sickle Cell Federation (ESCF)
European Hematology Association (EHA)
ERN-EuroBloodNet
Associação Portuguesa de Pais de Doentes com Hemoglobinopatias (APPDH) – also a Board Member
Loris Brunetta
Board Member of Thalassaemia International Federation (TIF),
Vice-chair of EHA Patients’ Advocacy Committee (PAC),
Member of the Patients and Consumer Working Party (PCWP) at EMA,
EMA expert on ESEC,
Former member of Committee for Orphan Medicinal Products (COMP) at EMA,
ePAG at EuroBloodNet,
Coordinator of the Italian Associations Advocacy Council (IAAC)
President of Associazione Ligure Thalassemici (Italy).
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an interview with Prof Kostas Stamatopoulos, as he shares his personal journey as both a medical doctor and a researcher in hematology and understand how these two activities have always been profoundly linked in his drive to deliver impactful solutions for patients - even though years may pass between a discovery and a change for patients in clinical practice.
Prof Stamatopoulos describes here his work into stereotypy of B-cell receptor (BCR) immunoglobulin and how this phenomenon explains the existence of the same or highly similar subsets of BCR clones in unrelated patients with CLL. Our guest explains further how this knowledge is leading to the classification of CLL patients into subsets with specific pathologies and might help personalize the treatment.
Next to translational research, Prof Stamatopoulos is focusing on patient empowerment. In this podcast, he will explain how he strives to create a more participatory healthcare model, and how he aims to transform education and training for young clinicians and researchers.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Kostas Stamatopoulos
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
This podcast episode is derived from the MDS Algorithm on EHA Campus. Check out the MDS Algorithm, which is an expert based tool for healthcare providers, ensuring a structured and evidence-based approach to managing myelodysplastic syndromes.
In this episode, our host Prof Kirsten Grønbæk from University of Copenhagen, discusses the management of high-risk MDS with Prof Katharina Götze from Technical University of Munich and Prof Valeria Santini from University of Florence. The experts delve into the two classification systems for MDS, defined by the International Consensus Classification (ICC) and World Health Organization (WHO) in 2022.
They discuss the impact of the similarities and discrepancies between these systems on clinical practice and the patients’ understanding of their disease. The speakers further talk about hypomethylating agents (HMA) as the backbone of current treatments for high-risk MDS. They exchange their views on the considerations for choosing the patients who are most likely to benefit from these treatments, while avoiding myelotoxicity. The experts also discuss selecting the right patients for other (emerging) treatments, such as venetoclax and magrolimab, while stressing that data from phase III trials is yet to become available for some of these agents.
The role of allogeneic transplantation as the only curative option for patients with high-risk MDS is also emphasized, with the experts highlighting the role of Molecular International Prognostic Scoring System (IPSS-M) in selecting the eligible patients. In the closing remarks, the importance and challenges of monitoring the molecular evolution of the disease are stressed, as this technology allows to tailor the available treatments to each individual patient.
Host: Prof Kirsten Grønbæk
Guests: Prof Katharina Götze & Prof Valeria Santini
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode on recent insights about metabolism of the hematopoietic stem cells (HSCs), Dr Krzysztof Szade from Jagellonian University in Krakow, Poland, discusses HSPc in health, aging and malignancy. This podcast recaps the findings that aim to elucidate the metabolic requirements of HSCs at different stages of aging.
Listen to Dr Szade summarize the data on how heme oxygenase-1 (HO-1) influences glycolytic metabolic stemness of HSCs, impacting on their self-renewal and differentiation. Follow his explanations of the hierarchical relationship between myeloid-biased and balanced HSCs and other observations shedding more light on the mechanisms of HSC aging. As the understanding of the metabolic requirements of HSCs during aging can point to new therapies for hematological disorders, tune in for this latest update.
Guest: Dr Krzysztof Szade
This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
This podcast episode highlights the need to use innovative clinical trial designs in the era of increasingly personalized medicine in hematology. Listen to Dr Jurjen Versluis from Erasmus Medical Center in Rotterdam, the Netherlands, discuss his research on this topic.
As the amount of novel targeted drugs is increasing, and treatments lead to increasingly better survival outcomes, we need to think about new, adaptive designs that will result in impactful trials in shorter time. Follow Dr Versluis as he explains the different designs and methods that can be used to estimate whether trial will be efficacious or futile before its completion.
The combination of clinical trials with data from existing real-world registries, such as HARMONY or Dutch Cancer Society datasets, may also be an alternative to standard designs. By using examples of trials run by HOVON, the Dutch Hemato-oncology Foundation, Dr Versluis provides additional depth to the discussion.
Guest: Dr Jurjen Versluis
This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
As knowledge about hereditary hematological malignancies (HHMs) increases, so do the options for better management of these diseases. Please join us in this podcast to hear Dr Kiran Tawana from Addenbrooke’s Hospital in Cambridge, UK, share her insights on this topic. HHMs are syndromes where two or more cases of cytopenia and hematological malignancy (typically MDS/AML) occur within the same family.
Dr Tawana discusses the discovery of HHMs and provides advice on how to recognize them in clinical practice, which can be hampered by low penetrance and significant differences in disease latency.
Listen to the stories of families affected by HHMs and how the molecular insights gathered from disease evolution in these case studies provide base for improved management of patients in the future. Tune in to hear the recommendations of dr. Tawana on how to optimize testing in clinical pathways and improve outcomes for people with HHMs.
Guest: Dr Kiran Tawana
This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, Prof Thorsten Zenz from University Hospital in Zurich, Switzerland, discusses the current approaches to treatment of relapsed hairy cell leukemia (HCL). Based on his personal journey as a hematologist interested in precision oncology, prof. Zenz summarizes the years of accumulating data and clinical experience to explain the treatment approach he often uses for his patients.
Thanks to the clear molecular target (V600E mutation of BRAF), treatment of classical hairy cell leukemia with BRAF inhibitors, such as vemurafenib, is an example of precision oncology that can result in deep responses. As combination of this treatment with anti-CD20 antibody leads to durable complete responses in most patients, Prof Zenz often uses this regime in his patients with refractory or relapsed hairy cell leukemia.
However, as different countries have access to different treatment options, Prof Zenz also discusses the role, sequencing and combinations of other drugs, such as to purine analogs (i.e. cladribine), MEK inhibitors, BTK-inhibitors, Bcl-2 inhibitors (i.e. venetoclax) or recombinant CD22-targeting immunotoxin (i.e. moxetumomab). In light of emerging (although still limited) data on these drugs and questions about their optimal sequencing, guidelines are being developed by Hairy Cell Leukemia Foundation (HCLF) and EHA that aim to help the clinicians with making choices for their patients.
This podcast is further enriched by insights from prof. Enrico Tiacci from University and Hospital of Perugia in Italy, who discovered that V600E mutation of BRAF is the key genetic lesion underlying hairy cell leukemia. Prof Tiacci shares his views on the treatment options and their sequencing, based on the clinical trials he conducted and his clinical experience.
Guest: Prof Thorsten Zenz
This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode of EHA Unplugged, Prof Kirsten Grønbæk and our guests Prof Yelena Ginzburg and Prof Amit Verma discuss iron metabolism and its role in erythropoiesis in MDS.
The experts share their views on the management of iron overload in the transfusion-dependent patients with MDS, as they acknowledge that it poses a real challenge in their clinical practice. Starting from the criteria used to select patients for iron chelation and then discussing its beneficial effects and limitations, the podcast guests formulate clear thoughts on the role of this therapy in both low- and high-risk MDS. They then clarify recent scientific insights into the putative mechanisms that may link iron overload with the ineffective erythropoiesis.
Please tune in to hear about the data from a mouse model pointing to the role of iron transport in erythroblast function and differentiation (please also see the Reference). You will also hear what direction the future research into the mechanism of the communication between ineffective erythropoiesis and iron metabolism may take.
This podcast is brought to you by EHA and the BioIron Society.
Host: Prof Kirsten Grønbæk
University of Copenhagen, Denmark
Guests:
Prof Yelena Ginzburg
Icahn School of Medicine at Mount Sinai, NY, USA
Prof Amit Verma
Albert Einstein College of Medicine, NY, USA
Reference: An W, et al. Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice. Elife. 2023 Dec 28:12:e83103. doi: 10.7554/eLife.83103
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, Dr Elisabeth Schorb from University Medical Center in Freiburg, Germany, discusses the first-line treatment of primary central nervous system lymphoma (PCNSL), which has seen tremendous advances in the last years. PCNSL is a rare condition, and because of its location prompt diagnosis and timely treatment are of the essence.
As for other hematological diseases, treatment of PCNSL today is based on two pillars: induction treatment and consolidation treatment. Listen to Dr Schrob describe her clinical experience and contributions to the international clinical trials that have shifted PCNSL prognosis from a disease with short life-expectancy if left untreated to a curable disease. And get inspired by Dr Schorb’s appeal to “stay tuned, stay in touch because your investigator-initiated ideas can make all the difference”.
Guest: Dr Elisabeth Schorb
This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
With the increasing scrutiny of healthcare pathways for women, this podcast provides a timely plea by Dr Michelle Lavin from St. James’s Hospital in Dublin, Ireland, to optimize global care for women with von Willebrand disease (VWD).
In this podcast, Dr Lavin gives a passionate appeal for more international collaboration and increased awareness to improve care for women and girls suffering from bleeding disorders. As challenges facing women with these disorders are multiple, including diagnostic inequalities and suboptimal treatments, the solutions are also multi-factorial. Listen to dr. Lavin give her recommendations to provide the best possible care, based on the findings from the Annual Global Survey of the World Federation of Hemophilia, World Bleeding Disorder Registry and other data.
In Dr Lavin’s own words: “there's momentum behind Women's Health”, so tune in to participate.
Guest: Dr Michelle Lavin
This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this lecture from EHA2024, Prof Domenico Girelli from University of Verona, Italy, discusses the complex relationship between iron metabolism and infection.
As an essential element for physiology of all living organisms, iron is involved in many vital processes, including our immune responses to infections. Since the pathogens themselves also depend on iron to survive, the resulting host/pathogen “battle” for iron is one of the key determinants of outcomes of most infectious diseases.
Interestingly, this dependence of pathogens on iron may offer a much-needed solution for multidrug resistance (MDR) of microbes, which poses a significant and growing challenge for the global healthcare. Tune in, to hear about the novel “metallo-antibiotics” and other clinical developments based on accumulating data about role of iron in infections.
Guest: Prof Domenico Girelli
This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an insightful lecture by Prof Maria Teresa Voso from University of Rome Tor Vergata in Italy, as she discusses the advances in the treatment of a rare subtype of AML, the acute promyelocytic leukemia (APL). As the PML::RARA rearrangement, resulting in a fusion protein that disrupts retinoic acid signaling and PML function, is the hallmark driver of APL, it is used as target for APL treatment.
Listen to Prof Voso as she talks about the scientific developments leading to significant improvements in clinical outcomes for patients with APL and the role of ATRA / ATO therapy, which combines all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).
Prof Voso highlights contributions of the late prof. Francesco Lo Coco, the significance of the EU-wide HARMONY registry and other collaborative efforts in establishing the optimal treatment regimens for APL. This podcast also provides insights into remaining open issues in the clinical management of APL, including high-risk APL for which the results of the much-anticipated APOLLO trial may provide some answers.
This is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. The podcasts in this series are better consumed in video form because of the accompanying slide content. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Guest: Prof Maria Teresa Voso
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this engaging debate on the future of acquired TTP (aTTP) treatment chaired by Dr. Eleni Gavriilaki from Aristotle University of Thessaloniki in Greece. This discussion features Prof. Marie Scully from University College London Hospital in UK and Prof. Paul Coppo from Saint-Antoine Hospital in Paris, France. The debate centers on whether therapeutic plasma exchange (PEX) combined with immunosuppression, long considered the standard treatment for acute aTTP episodes, has become obsolete with the advent of new therapies.
First Prof. Scully argues that plasmapheresis is indeed a thing of the past, citing its complexity and inherent safety concerns. Prof Scully predicts that the best alternative option will incorporate the use of recombinant ADAMTS13, caplacizumab and immunosuppression primarily with steroids and anti-CD-20 therapy.
In contrast, Prof Coppo argues that a PEX-free strategy cannot be universally applied to all aTTP patients, regardless of clinical presentation and severity because there is insufficient data yet to support this approach, the availability of caplacizumab is not guaranteed.
Tune in for this debate to hear further our experts’ views on the impact of treatment costs on availability and clinical decision making.
Guests:
Dr Eleni Gavriilaki
Aristotle University of Thessaloniki, Greece
Prof Marie Scully
University College London, UCLH, London, UK
Prof Paul Coppo
Sorbonne University and Saint-Antoine Hospital, Paris, France
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.
Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction.
The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't."
Host: Dr Wilson Lim
Guest: Dr Gregor Hormann
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Tune in to EHA Unplugged for an engaging chat with Professor Lars Bullinger from Charité University Medicine, Berlin. He'll break down the latest in myeloid disease classification, discussing how new genetic insights are transforming our understanding of MDS and AML.
Discover the hurdles clinicians face, the promise of innovative treatments, and the future of preventive medicine, including the impact of clonal hematopoiesis and cutting-edge sequencing tech.
Host: Prof Kirsten Grønbæk
Guest: Professor Lars Bullinger
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an insightful episode featuring Prof David Rees from King’s College Hospital in London as he discusses screening practices for Sickle Cell disease (SCD). Hosted by Dr Sarah de Vlieger, this discussion explores both antenatal and neonatal screening practices for Sickle Cell disease.
The conversation begins with an examination of antenatal screening challenges, comparing various techniques such as carrier screening, amniocentesis, chorionic villus sampling, and emerging non-invasive prenatal testing. Prof Rees and Dr de Vlieger then address the complex decisions arising from these test results and the disparities in screening access across different countries and cultures.
Moving to neonatal screening, Prof Rees emphasizes its crucial role in implementing early preventive measures. He advocates for the inclusion of Sickle Cell testing in general neonatal screening programs throughout Europe and aspires for screening to become more accessible in regions with higher disease prevalence.
Host: Sarah de Vlieger, EHA Head of Education
Guest: Prof David Rees
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future.
The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint.
Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.
Host: Dr Sarah de Vlieger
Guest: Dr Stephen Hibbs
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us in this podcast episode, exploring with Prof Matteo Della Porta (Humanitas Research Hospital, Milano, Italy) the emerging role of "synthetic patients" in hematological clinical trials. Innovative generative artificial intelligence models allow today to create synthetic data set based on real patients, suitable to be used as control groups in clinical trials, helping in the identification of disease mechanisms and improving the prognostic risk prediction.
Prof Della Porta will dig into the challenges and opportunities linked to these new technologies, from the overcoming of privacy barriers to the regulatory needs required with the advent of synthetic data in clinical trial settings, opening the door for novel models in clinical research.
Host: Dr Enrica Orsini
Guest: Prof Matteo Della Porta
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an insightful interview with Prof Bruno Paiva from Clinical University of Navarra in Pamplona, Spain, as he and our host Dr. Isabel Olivera-Martinez, discuss the latest technical approaches to improving monitoring, risk stratification and differential diagnosis of patients with monoclonal gammopathies including MGUS (monoclonal gammopathy of unknown significance), smoldering myeloma and multiple myeloma.
Prof Paiva begins by highlighting the importance of developing less invasive tools to assess MRD, given that multiple myeloma patients are living longer and need to be monitored multiple times.
He further describes the potential updates to the guidelines of the International Myeloma Working Group that may include the use of mass spectrometry, as a more sensitive method to quantify the M-component as well as the application of next-generation techniques - such as next-generation flow cytometry and next-generation sequencing- to monitor disease in peripheral blood, as a complement to bone marrow assessments.
Prof Paiva also discusses the two largest ongoing translational studies, which aim to elucidate the “unknown” and define the clinical significance of MGUS and smoldering myeloma for each individual patient.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Bruno Paiva
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an interview with Prof Ivo Touw, who has received the prestigious EHA David Grimwade Award for his contributions to the field of hematology research. Prof Touw and his research group focus on molecular signaling in leukemia predisposition syndromes, such as severe congenital neutropenia (SCN). They have described the dysfunction of the membrane receptor for the growth factor G-CSF and its role in SCN and malignant transformation to acute myeloid leukemia. In this interview prof.
Touw talks about his career path and choices that he has made along the way. He tells about his early fascination with the growth factors and how leukemia cells respond to them, which has driven his scientific career ever since. The simple questions such as “how can the growth factor in some cells only induce a proliferative response and in others both proliferation and differentiation?” or “why does one patient respond to G-SCF therapy and another does not?” triggered the discoveries of the complex underlying biological mechanisms.
If you want to hear about the stepwise discoveries of the roles of G-SCF mutants, RUNX gene and inflammatory stress and using novel technologies such as induced pluripotent stem (iPS) technology, CRISPR technology and computational biology, tune in to this episode with Prof Ivo Touw. He will also share his thoughts on the new avenues for thinking about therapy for SCN, such as repairing stem cells for autologous transplant or repurposing already available drugs.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Ivo Touw
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an insightful interview with Professor Saskia Middeldorp from Radboud University Medical Center in Nijmegen, The Netherlands, as she and our host Dr. Isabel Olivera-Martinez, discuss the medical and ethical challenges of conducting randomized clinical trials to prevent venous thromboembolism (VTE) during pregnancy.
VTE is a leading cause of maternal morbidity and mortality, and poses significant risks to pregnant women. Together, explore the relevance of prophylactic treatments like low molecular weight heparin, and the ethical and financial complexities of conducting trials in this population. Learn about the ALIFE2 trial results, that assessed whether LMWH heparin should be used in women with recurrent miscarriage and inherited thrombophilia; well as the latest research and guidelines aimed at improving care for pregnant women at risk of VTE.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Saskia Middeldorp
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our clinical case about Thrombosis and Hemostasis on the EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an insightful interview with Professor Frank Leebeek from Erasmus University in Rotterdam, The Netherlands, as he discusses together with our host, Dr. Isabel Olivera-Martinez, the potential of gene therapy to free hemophilia patients from the standard coagulation factor replacement therapy.
Prof. Leebeek explains how gene therapy for hemophilia is carried out and differentiates the current possibilities for hemophilia A patients versus those with hemophilia B. He also highlights the advantages and challenges of this life-changing therapy, including its long-term effects, while addressing patient concerns related to safety and accessibility. Finally, he provides a glimpse into the future of gene therapy.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Frank Leebeek
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our EHA Gene Therapy Techniques Program on the EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast episode, we will explore the application of artificial intelligence to morphological diagnosis in hematology. Listening to our host, Dr Mahesh Prahladan (University of Suffolk, UK) you will learn how innovative machine learning and deep learning models have led to the development of AI systems that have been applied in various areas of hematology, including digital pathology.
As these systems have shown promise in improving diagnostic accuracy and efficiency, they also have a potential for enlarging accessibility to precise diagnostics, through remote digital morphology, and have potential applications in the prognostic stratification of patients.
According to Dr Prahladan, we are not ready to dispose of our microscopes yet, but automation may become a useful and time-saving tool in the hands of morphologists.
Host: Dr Enrica Orsini
Guest: Dr Mahesh Prahladan
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain), the first academic centre to achieve the authorisation to treat patients with a CAR T therapy developed 100% by academia.
Prof Delgado discusses the complexities of obtaining regulatory approval for CAR T-cell therapy, under the EU regulation for advanced therapy medicinal products (ATMPs).
In this episode, Prof Delgado shares his own experience learning to navigate the EU regulatory expectations while working at the European Medicines Agency (EMA). He emphasizes the importance of scientists understanding these regulations and regulators understanding the specific position of academia in the approval pathway for ATMPs. Listen and take advantage of his valuable inshights!
Host: Isabel Olivera-Martinez, Medical Writer
Guest: Prof Julio Delgado
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this podcast discussing the promises and challenges of academic and point-of-care CAR T-cell manufacturing with Dr Anna Sureda, president of EBMT (European Society for Blood and Marrow Transplantation).
Dr Sureda provides her expert point of view on how CAR T-cells produced in academic centres may enhance patient access to CAR-T treatment, reducing costs and turnround times for production, and on the regulatory and quality issues linked to decentralized manufacturing of CAR T-cells.
Discover the current European landscape for academic CAR-T production, the evidence and experiences accumulated so far, and the potential role of scientific societies such as EBMT and EHA in shaping the future of CAR-T treatment.
Host: Enrica Orsini
Guest: Dr Anna Sureda
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain) as he explains the intricate process of CAR T-cell therapy. In this episode, we cover the key steps involved in CAR T, such as patient identification, apheresis, manufacturing, cell infusion and managing post-infusion related toxicities.
Prof Delgado offers expert insights on each component of this complex treatment and discusses possible improvements. He also highlights efforts to shorten vein-to-vein time and the importance of academic and non-profit manufacturing in reducing costs. This conversation offers a solid overview for clinicians and hematologists interested in advanced therapy medicinal products (ATMPs).
Host: Isabel Olivera-Martinez, Medical Writer
Guest: Prof Julio Delgado
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Tune in to our podcast for an in-depth discussion on CAR T-cell therapy for acute lymphocytic leukemia (ALL) in children. In this episode, we feature Professor Concetta Quintarelli, a renowned expert in hematology from the Bambino Gesù Children Hospital in Rome.
With host Isabel Olivera, they explore the advancements and challenges in treating ALL with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cells with other immunotherapies. The episode also delves into the complexities of the tumor microenvironment in ALL, antigen selection for targeted therapy, and the design of smarter CAR T-cells.
Professor Quintarelli discusses the future of CAR T-cell therapy, including the role of natural killer cells in ALL treatment and the importance of early intervention. Don't miss this insightful conversation on the latest developments in CAR T therapy for pediatric patients.
Host: Dr Isabel Olivera
Guest: Prof Concetta Quintarelli
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Tune in to our podcast for an in-depth discussion on immunotherapeutic strategies for Acute Myeloid Leukemia (AML). In this episode, we feature Dr Sarah Tettamanti, a senior scientist at the Fondazione Tettamanti Research Centre in Italy, who shares her expertise on CAR T-cell therapy for AML.
With host Dr Sarah de Vlieger, they examine the progress and challenges in treating AML with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cells with other immunotherapies.
The episode also covers the complexities of the tumor microenvironment in AML, antigen selection for targeted therapy, and the design of smarter CAR T-cells. Sarah discusses the future of CAR T-cell therapy, including fourth-generation CAR T-cells and the role of natural killer cells in AML treatment.
Host: Dr Sarah de Vlieger
Guest: Dr Sarah Tettamanti
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Welcome to a thought-provoking episode of our podcast series, where we dive into the ethical and practical challenges of CAR T-cell therapy with Professor Marie José Kersten from Amsterdam University Medical Centers.
In this episode, our host Dr Isabel Olivera engages in a deep dive with Professor Kersten on the intricacies of patient access to CAR T-cell therapy, the ethical considerations in patient selection, and the financial implications of this groundbreaking treatment.
Discover the rigorous process of patient eligibility assessment in the Netherlands, the national CAR-T tumorboard's role, and the ongoing efforts to make CAR T-cell therapy more accessible across different regions. Join us as we explore the potential of clinical trials in advancing treatment options, the quest for cost-effective manufacturing methods, and the critical importance of ethical decision-making in healthcare.
This conversation also offers valuable advice for hematologists and sheds light on the importance of multidisciplinary discussions in improving patient outcomes. Don't miss this insightful discussion that navigates the complexities of modern medicine and the future of lymphoma treatment.
Host: Dr Isabel Olivera Martinez
Guest: Prof Marie José Kersten
This is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma.
Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission.
Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions.
Host: Dr Sarah de Vlieger
Guest: Jonathan Clark
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024.
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for a captivating interview with our guest Professor Michael Hudecek from the Universitätsklinikum Würzburg in Germany as he offers his insights on the latest advancements in CAR T-cell therapy and gene-engineered immune cell therapies.
Together with our host Dr. Isabel Olivera Martinez, they discuss the mounting real-world data on CAR T-cell treatments and how AI is helping analyze this data to design new strategies and extend CAR-T to new indications.
Discover the strides being made to predict and manage treatment-related toxicities and to make CAR T-cell therapy more accessible and affordable, including potential off-the-shelf treatments and automated manufacturing techniques.
Learn about the role of gene editing and the challenges of creating universally compatible immune cell products. Finally, gain insights from the 2024 CAR T-cell meeting, where groundbreaking clinical updates and new applications of CAR-T to autoimmune and cardiovascular diseases were showcased.
Host: Dr Isabel Olivera Martinez
Guest: Prof Michael Hudecek
This is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us on this podcast episode featuring Prof. Maria Teresa Voso (Tor Vergata University of Rome, Italy) as she offers her insights on the latest advancements in precision medicine for diagnosing and treating myelodysplastic syndromes (MDS).
In this interview with our EHA host, Dr. Isabel Olivera Martinez, Prof. Voso begins by explaining how the use of NGS myeloid panels in identifying individual myeloid mutations enhances the diagnostic accuracy of MDS. Our guest then discusses the novelties in the 2022 WHO and ICC MDS classifications and the significance of germline predisposition. Furthermore, she explores the emerging targeted therapies for MDS, including lenalidomide, luspatercept, and imetelstat.
This episode offers a comprehensive overview of the evolving landscape of MDS diagnosis and management, highlighting the importance of personalized approaches in improving patient outcomes.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Maria Teresa Voso
This is the ninth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to MDS? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for a stimulating conversation with our guest Dr. Eleni Gavriilaki, from G. Papanicolaou Hospital and Aristotle University of Thessaloniki in Greece, as she shares her insights on one of her passions: diversity, equity, and inclusion (DEI) in hematology. Together with our host Dr. Sarah de Vlieger, they discuss the current challenges of DEI in the field and how organizations like EHA are addressing these issues.
They examine the importance of representation across gender, age groups and geographical location and how this impacts both clinical and research practices. Dr. Gavriilaki highlights ongoing initiatives to promote DEI, such as inclusive speaker selection, recruiting hematologists from diversity groups to leading roles, creating equitable grant opportunities. She further emphasizes the need for conscious efforts to provide opportunities to hematologists from underrepresented countries.
This conversation concludes with a call to action for hematologists who feel underrepresented to seize the current momentum and make their voices heard.
Host: Sarah de Vlieger, EHA Head of Education
Guest: Dr. Eleni Gavriilaki
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for a captivating interview with our guest Professor Carl June, Director of the Centre for Cellular Immunotherapies at the University of Pennsylvania, USA, as he discusses the current directions in CAR T-cell therapy.
Together with our host Dr. Sarah de Vlieger, they examine the latest results on both pediatric and adult patients with over ten years of follow up. They cover ongoing trials aimed at drastically reducing the vein-to-vein time for autologous CAR T-cells, as well as trends toward academic manufacturing and the full automation of production processes.
Finally, Prof. June provides insight into USA FDA’s warning about secondary malignancies in CAR T-cell-treated patients issued in November 2023.
Host: Sarah de Vlieger, EHA Head of Education
Guest: Prof Carl June
This is the first of a series of podcasts recorded at the 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for a discussion with Prof Paolo Ghia, MD, PhD, from Università Vita Salute San Raffaele, Milan (Italy), as he explores how precision medicine is transforming CLL treatment.
In this episode, discover how precision medicine is used daily in CLL to decide the best management and treatment for patients. Listen to Prof Ghia explain how CLL management is moving from traditional chemotherapy to targeted therapies based on specific genetic markers, like immunoglobulin mutational status or P53 aberrations, which help guide treatment decisions.
Explore the array of targeted therapies available for CLL, including BTK inhibitors and BCL-2 inhibitors, and understand how they target critical pathways in CLL pathogenesis. Gain insights from Prof Ghia on the complexities of selecting the right therapy for each patient based on genetic profile, disease risk, and individual preferences.
Through the discussion, recognise the challenges in CLL management, such as relapse scenarios and emerging therapies, and learn the research strategies being explored for potential cures in CLL
This is a series of podcasts covering precision medicine across several disorders, more podcasts will be available in the future. Stay tuned!
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Lucia de Franceschi
This is the eighth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to CLL? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us on this podcast episode featuring Prof Lucia de Franceschi (Department of Medicine, University of Verona, Italy) as she discusses the latest advances on the use of Pyruvate kinase activators in the treatment of rare hematological diseases.
Learn about the crucial role of Pyruvate kinase (PK) in erythrocyte metabolism and how pyruvate kinase activators are emerging as a new therapeutic option for chronic hemolytic anemias that had previously no other treatment than transfusion or iron chelation.
Discover how two oral pyruvate kinase activators, Mitapivat and Etavopivat, can help improve ineffective erythropoiesis and survival of red cells and therefore are being tested as a new therapeutic scenario for non-transfusion dependent thalassemia patients and sickle cell disease patients.
Discover how PK activators are able to reprogram red cells to a more normal metabolite context, which can have a beneficial effect in a wide range of rare diseases all characterized by an abnormal metabolite profile, which represents the ideal breakthrough in the management of rare diseases, as one drug has the ability to treat multiple disorders.
This is a series of podcasts covering precision medicine across several disorders, more podcasts will be available in the future. Stay tuned!
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Lucia de Franceschi
This is the seventh episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn MoreMatte, Alessandro, Enrica Federti, and Lucia De Franceschi. 2023. ‘Erythrocyte Pyruvate Kinase Activation in Red Cell Disorders’. Current Opinion in Hematology 30 (3): 93. https://doi.org/10.1097/MOH.0000000000000758.
Interested in more content related to Thalassemia? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this captivating interview with our guest Prof Stefano Luminari, MD, PhD, from the University of Modena and Reggio Emilia in Italy, as he explores what precision medicine means today for follicular lymphoma.
Together with our host Dr. Isabel Olivera-Martinez, they discuss the current precision medicine approaches to the diagnosis and treatment of follicular lymphoma. They explore the molecular events underlying the disease, the latest targeted therapies, and the future of treatment for follicular lymphoma. Professor Luminari shares his insights on the most promising developments in the field, including T cell engagers, bispecific antibodies, and CAR-T therapies. He also discusses the importance of considering not only the efficacy of these treatments but also their impact on the quality of life and long-term outcomes for patients. This episode provides a comprehensive and enlightening discussion on the current state and future of follicular lymphoma treatment.
This is a series of podcasts covering precision medicine across several disorders, more podcasts will
be available in the future. Stay tuned!
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Stefano Luminari
This is the sixth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn MoreInterested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for a captivating discussion with Prof Pieter Sonneveld, MD, PhD, from Erasmus MC Cancer Institute in Rotterdam, the Netherlands, as he explores the evolution of precision medicine in multiple myeloma.
Prof. Sonneveld outlines the improvements in multiple myeloma treatment over the past decade, describing the progressive addition of targeted therapies such as daratumumab and bispecific antibodies, BiTEs, and CAR-T cells to the therapeutic arsenal.
Discover how treatment selection now hinges on whether a one-off or continuous therapy is most suitable, acknowledging the challenges of limited availability in Europe due to cost considerations. Learn about the outstanding findings from the phase III PERSEUS trial, demonstrating the effectiveness of daratumumab combined with lenalidomide for newly diagnosed transplant-eligible patients and transforming their standard of care.
This interview unveils cutting-edge strategies that are reshaping myeloma prognosis and underscores the importance of early adoption of novel therapies for improved patient outcomes.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Peter Sonneveld
This is the fifth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn MoreIf you'd like to learn more about Multiple Myeloma, check out the comprehensive EHA - Multiple Myeloma Program on EHA Campus.
Interested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Welcome to this podcast episode featuring Prof Claire Harrison (Clinical Director at Guy’s and St Thomas’ NHS Foundation Trust) and Prof Jean-Jacques Kiladjian (Professor at Université Paris-Diderot and Hôpital Saint-Louis).
Join them as they navigate the challenges and opportunities of precision medicine in MPNs, discover how advancements in molecular techniques are reshaping disease diagnosis, patient stratification and treatment tailoring.
Gain insights into the evolving landscape of targeted therapies for MPNs, including JAK inhibitors and emerging strategies for CALR mutation targeting.
Listen as our experts highlight the heterogeneity of clinical needs based on individual patients' molecular profiles and the promise of personalised treatment approaches bringing exciting prospects for improving patient outcomes in this dynamic field.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Claire Harrison and Prof Jean-Jacques Kiladjian
This is the fourth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn MoreIf you'd like to learn more about MPN, check out the EHA - Myeloproliferative Neoplasms Program on EHA Campus.
Interested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us on this podcast episode featuring Prof Helen Papadaki (University of Crete, Greece) as she discusses the link between clonal hematopoiesis and the risk of developing MDS or AML.
Prof. Papadaki begins by explaining the difference between CHIP (clonal hematopoiesis of indeterminate potential), CCUS (clonal cytopenia of undetermined significance) and ICUS (Idiopathic cytopenia of undetermined significance). She underlines the clinical relevance of the association of clonal hematopoiesis with cytopenias, as a clear indicator of an increased risk of developing hematological malignancies.
Learn how important it is to better characterize by NGS sequencing the specific mutations of the clones, given that the type of mutation, the number of mutations, and the combination of mutations are critical parameters in accurately predicting the risk of developing MDS or AML.
Furthermore, Prof Papadaki explains the importance of discriminating between acquired and germline mutations leading to clonal hematopoiesis and their relationship with age. Finally, she highlights the fact that clonal hematopoiesis is a risk factor for developing not only hematological malignancies but also cardiac diseases.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Helen Papadaki
This is the third episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us on this podcast episode featuring Prof Domenico Girelli, Professor of Internal Medicine and Director of the Internal Medicine Unit, University Hospital of Verona (Italy), as he discusses the latest advances on the use of Hepcidin mimetics in the treatment of Polycythemia Vera and iron metabolism diseases.
Discover how Hepcidin analogues offer a precise method for managing the overproduction of red blood cells in Polycythemia Vera patients. Explore the potential of Rusfertide, an inhibitor of Hepcidin, in regulating iron availability for erythropoiesis, thereby addressing the characteristic and chronic erythrocytosis seen in Polycythemia Vera. Gain insights into how targeting the Hepcidin-Ferroportin axis is revolutionizing the treatment of various iron metabolism disorders.
Tune in for a comprehensive discussion on these groundbreaking advancements in hematology research.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Domenico Girelli
This is the second in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn MoreTo go further: Kremyanskaya M et al. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22;390(8):723-735. doi: 10.1056/NEJMoa2308809. PMID: 38381675.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Welcome to another season of EHA Unplugged. In our first episode of 2024, listen to Prof Carlo Dufour, Chairperson of the Paediatric Hemato-Oncology department of G. Gaslini Children’s Hospital in Genova (Italy), as he discusses how classical IBMFs (such as Fanconi Anemia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome, and the telomere disorders) are now being joined by a large number of other diseases included in this category, thanks to the increasing precision of diagnostic genetic tools.
Prof Dufour explains further how crucial precise genetic-based diagnosis is in discriminating between true acquired and constitutional bone marrow failure disorders in order to properly determine the best line of treatment for these rare diseases and to establish a monitoring plan to prevent the occurrence of secondary malignancies.
Tune in to find out how IBMFS patients may benefit from precision medicine and a therapy tailored to their genetic constitution.
This is a series of podcasts covering precision medicine across various disorders, more podcasts will be available in the future. Stay tuned!
Guest: Prof Carlo Dufour, G. Gaslini Children’s Hospital in Genova (Italy)
Host: Isabel Olivera-Martinez, PhD, European Hematology Association (EHA)
Learn MoreTo go further: Miano M, Grossi A, Dell'Orso G, et al. Genetic screening of children with marrow failure. The role of primary Immunodeficiencies. Am J Hematol. 2021; 96(9): 1077–1086. https://doi.org/10.1002/ajh.26242
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, join HemaSphere's editor-in-chief, Prof Jan Cools, as he guides you through article publishing. Acquire valuable insights, tips, and new perspectives on often-overlooked considerations. Prof Cools sheds light on the pivotal role of reviewers in the publishing process and provides his insights into the evolving impact of AI on publishing.
Guest: Prof Jan Cools, KU Leuven. Belgium. Editor-in-Chief of HemaSphere
Host: Dr Wilson Lim, European Hematology Association (EHA)
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Welcome to EHA Unplugged! In this episode, join host Dr Wilson Lim as he delves into the world of hemochromatosis with esteemed Prof Domenico Girrelli from the University of Verona.
Prof Girrelli provides valuable insights into the new classification of hemochromatosis, shedding light on its genetic determinants, clinical manifestations, and recent advancements in its diagnosis and treatment. Discover the complexities of iron metabolism and the impact of this classification on patient management.
Tune in to stay informed about the latest developments in hemochromatosis classification.
Guest: Prof Domenico Girrelli, University of Verona, Italy
Host: Dr Wilson Lim, European Hematology Association (EHA)
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode Prof Tarec El-Galaly gives an overview of diversity, equity, and inclusion (DEI). He explains what is DEI in hematology and the work EHA taskforce DEI taskforce is doing for patients benefit. Listen to this great initiative and perhaps it can benefit your practice.
Guest: Prof Tarec El-Galaly, Aalborg University Hospital, Denmark
Host: Dr Wilson Lim, European Hematology Association (EHA)
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this update on Autoimmune Neutropenia (AIN), a rare blood disorder that presents and develops differently in children and adults.
Experts Dr Francesca Fioredda and Prof Helen Papadaki along with our host Dr. Isabel Olivera discuss the diagnostic challenges associated with AIN and the need for a broader definition, based on the latest insights from the different mechanisms underlying AIN’s pathogenesis.
Learn how to adapt the treatment of AIN to the specific form of neutropenia, the patient’s age, evolving needs, and underlying disease. Our experts also emphasize the importance of carefully monitoring AIN patients and of maintaining accurate patient registries.
Read this review article on AIN at HemaSphere or follow the AIN course on the EHA Campus to learn more about AIN.
Host:
Dr. Isabel Olivera
European Hematology Association
Guests:
Dr Francesca Fioredda
Istituito Giannina Gaslini, Italy
Prof Helen Papadaki
University of Crete School of Medicine, Greece
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us in this enlightening podcast as three experienced researchers, Dr Anastasia Conti, Prof Konstanze Döhner, and Dr Simona Valletta, delve into the dynamic world of scientific research. This discussion moderated by Prof Kirsten Grønbæk offers valuable insights into the pivotal aspects of successful careers in research for hematologists.
The conversation dives deeply into topics relevant to aspiring and established researchers, such as the crucial role of mentorship, and the importance of female mentors in the field, as they may offer valuable guidance to women in science. Choosing the right research lab, the need for a work-life balance, and how to balance clinical work with research endeavors for clinician-scientists are other valuable insights shared by the panel.
The podcast concludes with a focus on fostering a supportive work environment for researchers. They emphasize flexibility, strong communication, and the importance of respecting boundaries to maintain a positive and productive lab atmosphere.
Tune in to gain a wealth of knowledge for navigating in the world of scientific research in hematology.
Host:
Prof Kirsten Grønbæk
Rigshospitalet and BRIC, Denmark
Guests:
Dr Anastasia Conti
San Raffaele Telethon Institute for Gene Therapy, Italy
Prof Konstanze Döhner
University Hospital of Ulm, Ulm, Germany
Dr Simona Valletta
University of Manchester, United Kingdom
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join Prof Kirsten Grønbæk and Prof Konstanze Döhner as they talk about the current landscape in MDS. Prof Grønbæk shares her interest and passion in the disease, the challenges in diagnosis and treatment, and what is on the horizon in research and management of MDS.
Guest: Prof Kirsten Grønbæk, Rigshospitalet and BRIC, Copenhagen, Denmark
Host: Prof Konstanze Döhner, University Hospital of Ulm, Germany
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, expert Prof Paresh Vyas and host Dr Enrica Orsini delve into the latest developments in the treatment of Acute Myeloid Leukemia (AML). They discuss new drug targets, new therapies in clinics and the impact of the new treatment on aging patients Moreover, they address existing challenges and provide a glimpse into what the future holds for AML treatment.
Guest: Prof Paresh Vyas, University of Oxford, United Kingdom
Host: Dr Enrica Orsini, EHA
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for this insightful podcast where our experts Prof Kirsten Grønbæk, Dr Mirjam Belderbos, Dr Umut Yilmaz, and Prof Konstanze Döhner discuss their experiences, challenges, and strategies for thriving in their demanding and rewarding careers as hematologists. They share valuable insight from effective communication with patients and caregivers to coping with the emotional aspects of their work. Discover how they strike a balance between personal well-being and professional responsibilities.
Host:
Prof Kirsten Grønbæk,
Rigshospitalet and BRIC, Copenhagen, Denmark
Guests:
Dr Umut Yilmaz
İstanbul University-Cerrahpaşa, Istanbul, Turkey
Prof Konstanze Döhner
University Hospital of Ulm, Ulm, Germany
Dr Mirjam Belderbos
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
Learn MoreIf you'd like to continue learning about patient communication, check out the course The Divided Brain: Emotion vs. Logic in Patient Communicationon EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Guest Prof Kimmo Porkka together with host Dr Enrica Orsini talk about using big data to build prognostic models. Based on Prof Porkka’s experience on working with big data, he uses the Harmony Alliance as an example and gives an overview of data collection, the importance of data security and the importance to have the participation of a large network of hospitals or academic centers, and recognising the challenges behind that.
Guest: Prof Kimmo Porka. University of Helsinki, Finland
Host: Dr Enrica Orsini, EHA.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Prof Jorge Sierra provides an overview of myeloma, delving into its clinical aspects and sharing his personal passion for the disease.
Together with host Prof. Konstanze Döhner, they explore myeloma's treatment challenges and advancements. Prof. Sierra also offers valuable advice on initiating myeloma research, making this an engaging podcast for students, trainees, and young hematologists alike.
Guest: Prof Jorge Sierra
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Host: Prof Konstanze Döhner
University Hospital of Ulm, Ulm, Germany
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, we talk to Dr. Umut Yilmaz from İstanbul University-Cerrahpaşa. Umut shares his interest in lymphoma, its diversity, and the challenges in his work. He also offers unique advice for inspiring starting hematologists and calls for more people to join the exciting field of lymphoma research and treatment.
Guest: Dr Umut Yilmaz
İstanbul University-Cerrahpaşa, Istanbul, Turkey
Host: Prof Kirsten Grønbæk
Rigshospitalet and BRIC, Copenhagen, Denmark
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Our guests Dr Anastasia Conti, Assoc Prof Maria Paola Martelli and Dr Simona Valletta give an overview on starting research in hematology. They go through their experience, give advice and talk about the challenges they face.
The podcast starts with the basics of how to get started in hematology research, starting how to come up with research ideas and how to develop these ideas into projects. Our guests continue with their view on PhD programmes, where they give advice to those who want to start a PhD or a research focused career. Anastasia, Maria and Simona recollects how rewarding their PhD experience was and emphasizes the importance of motivation, resilience and persistence in research. A PhD shapes you Simona says. Last but not least, they delve into the topic of research funding and their experiences in writing grants.
Guests:
Dr Anatasia Conti
San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
Assoc Prof Maria Paola Martelli
University of Perugia, Perugia, Italy
Dr Simona Valletta
University of Manchester, Manchester, United Kingdom
Host: Prof Kirsten Grønbæk
Rigshospitalet and BRIC, Copenhagen, Denmark
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as guest Dr Mirjam Belderbos talk to our host Prof Kirsten Grønbæk about her own experience in pediatric hematology, how she interacts with her patients and their family, the challenges in the field and how it differs from adult hematology. She also indulge us in the fun annual custom her pediatric unit does and how rewarding her role is to her. She ends by giving some advice to trainees and medical students who are interested in the field of pediatric hematology.
Guest: Dr Mirjam Belderbos. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
Host: Prof Kirsten Grønbæk. Rigshospitalet and BRIC, Copenhagen, Denmark
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
This week, we have guest Prof Laura Silvestri from Vita-Salute San Raffaele University who gives an amazing overview of iron regulation from the perspective of the protein hepcidin.
Prof Silvestri illustrates the mechanism behind hepcidin regulation and how is transcription effected by proinflammatory cytokines in certain hematological disorders.
Host: Dr Enrica Orsini; Guest: Prof Laura Silvestri
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, Prof David Rees gives an overview of acute chest syndrome (ACS) in SCD.
Prof Rees and host Dr Enrica Orsini talk about epidemiology, the clinical picture, patient management, and the importance of recognizing this disease.
Host: Dr Enrica Orsini; Guest: Prof David Rees
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, Prof Maria Teressa Voso talks about MDS classification and risk assessment. She explains the different risk scores, the importance of molecular genetics in classification, risk stratification and management in MDS patients.
Guest: Prof Maria Teressa Voso ; Host: Dr Enrica Orsini
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as our guest Prof. Martina Muckenthaler and host Dr. Isabel Olivera Martinez give an overview on anemia of inflammation. They discuss the pathogenesis of the disease and the current treatment landscape in particular with HIF-PH inhibitors, and hepcidin as a target in certain disease entities.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
Guest: Prof. Martina Muckenthaler ; Host: Dr. Isabel Olivera Martinez
Learn more: Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as Dr. Maria Themeli and Dr. Ciprian Tomuleasa provide an overview of the latest developments and novel ideas in CAR-T therapy.
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
Guests: Dr. Maria Themeli and Dr. Ciprian Tomuleasa
Learn more: Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as Dr. Anna Sureda explains the available CAR-T treatments for lymphomas, focusing on DLBCL (diffuse large B cell lymphoma) and the challenges of CAR-T therapy in the current treatment landscape. She also considers the possibility of using CAR-T cells in 2nd line treatment (or earlier) and in combination with other drugs.
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
Guest: Dr Anna Sureda
Learn more:
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode Dr Wilson Lim interviews our guest Prof. Carlos Fernández de Larrea on CAR-T toxicities and how to control or avoid adverse reactions to CAR-T therapies in patients with myeloma.
Guest: Prof. Carlos Fernández de Larrea ; Host: Dr Wilson Lim
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
Learn more:
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as Dr. Anna Sureda discusses CAR-T therapy from a patients perspective and the steps that physicians can take to help patients overcome the challenges that comes with CAR-T treatment.
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
Guest: Dr Anna Sureda ; Host: Dr Wilson Lim
Learn more:
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as Emeritus Prof Robin Foà brings you on the journey of Ph+ ALL management together with our host Dr Enrica Orsini. With a long career in ALL, Prof Foà runs through the history of Ph+ ALL, his experience in patient management, and then brings you up to date on the current picture in patient management.
Tune in as Prof Foà describes the breakthrough in treatment with TKI inhibitors and the introduction of the immunotherapeutic drug blinatumomab in Ph+ ALL.
Guest: Emeritus Prof. Robin Foà
Host: Dr. Enrica Orsini
Learn more:
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for another episode of EHA Unplugged. We have Prof. Herman Einsele here talking about the current landscapes of CAR-T therapy in myeloma, results achievable today, and the future perspectives for these patients.
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
Guest: Prof Herman Einsele
Learn more:
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us here at EHA Unplugged with another episode on CAR-T updates. Listen as our guest Prof. Chiara Bonini and host Dr. Wilson Lim discuss the reasons for CAR-T therapy failure and relapse after treatment.
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
If you liked this podcast and would like to explore related content, you can check out our CAR-T program on the EHA Campus.
Guest: Prof. Chiara Bonini ; Host: Dr. Wilson Lim
Learn More:
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as Prof. Christian Chabannon provides an overview of the challenges and obstacles raised by the economic aspects of CAR-T treatment. He examines different solutions and proposes a way forward to address these issues.
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
If you liked this podcast and would like to explore related content, you can check out our CAR-T program on the EHA Campus.
Guest: Prof. Christian Chabannon ; Host: Dr. Olivera Martinez
Learn More
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as Prof. John Gribben provides an update on where we are with CAR-T in acute and chronic leukemias.
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our CAR-T program on the EHA Campus.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Prof Günter Weiss, from the University of Innsbruck, Germany, provides in this podcast a comprehensive pathogenetic and clinical overview of a relevant and frequent medical problem: Absolute Iron Deficiency, defined as the combination of anemia of chronic disease (ACD) and iron deficiency anemia (IDA) in people suffering from inflammatory disorders.
The complex functional mechanisms and underlying diseases at work in these patients make the diagnostic work-up and treatment choices difficult and may require careful analysis. Prof Weiss’s clear explanation of the different issues associated with this condition provides a useful guide to clinicians in their daily practice.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our EHA Diagnosing And Treating Iron Deficiency Program on the EHA Campus.
EHA Social LearningExplore our social media microlearning: https://ehaedu.org/SM_Learning
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen as Prof. Carl June provides an overview of the past and current landscape and challenges in CAR-T therapy, along with a summary of the innovations being introduced to lower the cost of CAR-T and improve CAR-T treatment and access.
This podcast episode is part of our FREE course on CAR-T Updates on the EHA Campus. Prominent experts provide an overview of CAR-T treatment in different diseases, discussing clinical management, economic and regulatory aspects, and future developments.
What did you think of this podcast? Share your opinions with us in a short feedback survey.
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our CAR-T program on the EHA Campus.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, Hartmut Döhner, Hematologist-Oncologist and Professor of Medicine in Germany, discusses with Dr. Nathalie van Havre the role of genomic characterization in the classification, prognosis and treatment of myeloid neoplasms.
Discover the main methods of genomic testing, the kind of relevant information they can provide, and the essential techniques that should currently be available for hematology centers. The podcast also explores the significance of germline variants and the need for their investigation, and the challenges associated with the implementation of a comprehensive genomic assessment in routine clinical practice.
The podcast is based on the paper: "Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia", by Duncavage EJ, et al. Blood. 2022;140:2228-2247. (https://pubmed.ncbi.nlm.nih.gov/36130297/)
Host: Dr Nathalie van Havre; Guest: Prof Hartmut Döhner
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast about gene therapy for hemoglobinopathies, our experts Dr. Evangelia Yanaki and Professor Franco Locatelli discuss the most effective approach for treating patients with these conditions, considering the safety concerns and potential complications associated, as well as the need for long-term monitoring of patients.
In this debate recorded during the EHA22 Annual Congress, Dr. Yanaki advocates for gene addition therapy, while Professor Locatelli favors genome editing as a more precise approach. Despite their differing opinions, both speakers concur that additional research is necessary to fully comprehend the potential benefits and risks of both approaches.
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our EHA Gene Therapy Techniques Programon the EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode, guest Prof Martin Dreyling and host Dr Nathalie van Havre discuss the latest developments in lymphoid malignancies and the research roadmap that has been put in place to guide future research.
Professor Dreyling highlights the move away from traditional chemotherapy towards non-cytostatic approaches and discusses the long-term complications of traditional treatments and the need for precision therapy.
Host: Dr Nathalie van Havre; Guest: Prof Martin Dreyling
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this episode of EHA Unplugged, Prof Beverly Hunt discusses the global consequences of postpartum hemorrhage (PPH) and the unacceptable PPH-related mortality rate in developed countries. The discussion continues on the challenges faced in the identification of PPH and the primary causes of PPH. Prof Hunt further talks about the consequences of PPH on children and emphasizes the need for more research in PPH and campaigns to improve maternal health.
Guest: Prof Beverly Hunt
This podcast was recorded as a Spotlight Talks session during EHA2022. More podcasts from EHA2022 will be available. Stay tuned.
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our Women with Bleeding Disorder course on the EHA Campus. A multidisciplinary team of experts has developed this accredited micro e-learning program to increase awareness, knowledge, and understanding of bleeding disorders and their management among healthcare professionals who are the first to see women and girls with signs and symptoms of bleeding disorders.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join Prof Paolo Ghia and our host Dr Enrica Orsini as they discuss the treatment of Chronic Lymphocytic Leukemia (CLL) from the perspectives of patients and doctors.
In this episode, they discuss the factors that influence the decision of treatment choices from the perspectives of patients and doctors and how both parties have different perspectives on the subject. They further highlight the importance of understanding the differing priorities between these two groups and the need for shared decision-making in the treatment process.
The podcast is based on the paper: "What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment", by Laurenti L et al., published on HemaSphere in 2022.
Host: Dr Enrica Orsini; Guest: Prof Paolo Ghia
Learn MoreTo learn more about CLL and updated treatment recommendations, check out our comprehensive CLL Program on the EHA Campus.
Discover more of EHA's social media microlearning here.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Treatment of low-risk patients with polycythemia vera (PV) and myelofibrosis (MF) is still a matter of debate. Although traditionally these patients were managed exclusively with supportive treatment, more recent guidelines suggest the opportunity of identifying subgroups of patients eligible for cytoreduction.
In this debate recorded during the EHA22 Annual Congress, experts Claire Harrison and Christen Lykkegaard Andersen support opposite statements on this topic, discussing the pros and cons of cytoreductive treatment in low-risk PV and MF patients, with the aid of representative clinical cases.
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our Polycythemia Vera course on the EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join our guest Dr Martin Kaiser and host Dr Nathalie van Havre, as they talk about Heath Technology Assessment (HTA) in hematology and in Europe’s public healthcare landscape.
Our speakers discuss the relevance of HTA for hematologists and how it aims to standardize access to new health technologies for patients across Europe. Furthermore, they examine the challenges in generating solid evidence to support these assessments, particularly in the case of rare diseases, and whether HTAs are likely to cause new delays for new health technologies to reach the patients.
Next, the social and economic implications of HTA are discussed, in particular costs, limited resources, and equality in access to treatment. Dr Kaiser concludes this podcast by emphasizing the importance of HTA education and awareness in medical education.
Host: Dr Nathalie van Havre; Guest: Dr Martin Kaiser
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, you will listen to Prof Antonis Kattamis summarizing the last developments in the treatment of patients with thalassemia. While the life expectancy of these patients has considerably improved in the last decades, quality of life and disease burden is still a relevant issue.
However, new classes of drugs, with action of the pathophysiologic mechanisms of the disease, are entering the clinics—drugs able to improve globin chain imbalance or ineffective erythropoiesis, or decrease hemolysis. Prof Kattamis will discuss the efficacy of these treatments and of innovative gene therapy approaches, not neglecting economic evaluations on the sustainability of new treatments in thalassemia.
Guest: Prof Antonis Kattamis
This podcast was recorded as a Spotlight Talks session during EHA2022. More podcasts from EHA2022 will be available in the future. Stay tuned!
View this podcast on EHA Campus for key slides related to this episode.
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our EHA Thalassemia Program on the EHA Campus.
For more social media microlearning from EHA, visit https://ehaedu.org/SM_Learning.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive EHA Educational Updates via https://eha.news/subscribe
In this podcast, Prof Paolo Ghia discusses the current treatment landscape of Chronic Lymphocytic Leukemia (CLL), providing a guide for clinicians faced with an ever-growing number of therapeutic alternatives.
Within targeted therapies, a special focus is dedicated to BTK inhibitors and their different characteristics, and to the long-term results of the ASCEND trial. The management of CLL is changing rapidly, and Prof Ghia's expertise can help hematologists to choose the right treatment for their patients, even in high-risk cases, such as the ones with TP53 mutation or del(17p).
The podcast is based on the paper: "Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results", by Ghia P et al., published on HemaSphere in 2022.
Host: Dr Enrica Orsini; Guest: Prof Paolo Ghia
Learn MoreTo learn more about CLL and updated treatment recommendations, check out our comprehensive CLL Program on the EHA Campus.
Discover more of EHA's social media microlearning here.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, Prof Mario Cazzola illustrates the genesis of the new ICC classification of myeloid neoplasms, published in 2022 (Arber DA et al, Blood 2022), with a special focus on MDS, and the new nosological entities that have been defined in it.
The new entities, namely SF3B1-mutant MDS, TP53 multi-hit MDS, and clonal cytopenia of undetermined significance (CCUS), underline the importance of gene sequencing for the diagnosis and risk stratification of myeloid neoplasms and MDS in particular.
Guest: Prof Mario Cazzola
This podcast was recorded as a Spotlight Talks session during EHA2022. More podcasts from EHA2022 will be available in the future. Stay tuned!
View this podcast on EHA Campus for key slides related to this episode.
Learn MoreIf you liked this podcast and would like to explore related content, you can check out our MDS Flashcards on the EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
What are the latest guidelines for the management of patients with Transfusion-Dependent Thalassemia (TDT)?In 2022, the fourth edition of the TIF (Thalassemia International Federation) guidelines for the management of patients with transfusion-dependent thalassemia (TDT) was published.
In this podcast, Prof Ali Taher discusses with our host, Dr Nathalie van Havre, the main news of this edition, including genetic work-up, chelation therapy, and prevention and management of complications.
Furthermore, Prof Taher illustrates the innovative gene therapy approaches and new drugs (such as luspatercept, the most recently approved drug for TDT) currently available for the treatment of these patients and how they can impact the management of TDT.
The podcast is based on the paper "2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia", by Farmakis D et al., published in HemaSphere in 2022 (HemaSphere. 2022;6:e732).
Host: Dr Nathalie van Havre; Guest: Prof Ali Taher
This is the sixth of a series of podcasts discussing recently published scientific articles. More podcasts will be available in the future. Stay tuned!
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Spotlight Talks: Updates on the Classification of Hematolymphoid Neoplasms: Lymphoid DiseasesIn this podcast, Prof John Gribben, former President of EHA, discusses the new ICC lymphoid malignancies classification (Campo E, et al. Blood, 2022), highlighting the main novelties introduced for specific entities and explaining the new criteria guiding the diagnosis and prognosis of lymphoproliferative diseases.
Listen to this podcast to gain an overview of the most innovative findings in the field, while waiting for the updated WHO classification to be published in 2023.
Guest: Prof John Gribben
This podcast was recorded as a Spotlight Talks session during EHA2022. More podcasts from EHA2022 will be available in the future. Stay tuned!
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Is CAR-T economically sustainable?Join our guest Prof Martin Dreyling and host Dr Nathalie van Havre as they discuss the costs of CAR-T cell therapy for the treatment of blood disorders at an individual level and whether it is economically sustainable for health systems.
Listen along as they consider the financial challenges of patient selection for this costly life-saving therapy, based on Prof Dreyling’s experience with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) patients. Challenges touched upon include reimbursement policies, time lags and associated costs of personalized therapy, and choosing the indications to include.
Prof Dreyling further offers his insights into the overall financial burden for health systems based on his participation on a recent Budget Impact Analysis (BIA) carried out in DLBCL patients in Germany. Finally, our guests contemplate cancer immunotherapy perspectives for the coming years, including bispecific antibodies as a potentially cost-effective alternative in development.
The details of the BIA were recently described in the article Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany published in HemaSphere by Skalt D, Moertl B, von Bergwelt-Baildon M, Schmidt C, Schoel W, Bücklein V, Weiglein T, Dreyling M, and Berger K.
Host: Dr Nathalie van Havre; Guest: Prof Martin Dreyling
This is the fifth of a series of podcasts discussing recently published scientific articles. More podcasts will be available in the future. Stay tuned!
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
What is Plan S and what has happened to it?Join our guest Dr Nuno Borges and host Dr Christian Scharenberg as they talk about the core principles, goals, and challenges of Plan S.
Listen along as Dr Borges discusses the controversies aroused by Plan S and the “publish or perish” paradigm faced by early career scientists. Dr Borges ends this podcast on a positive note where he believes that slowly, but surely, and thanks to social media, we are heading towards a future where scientific publications will be open access and freely available to everyone.
This discussion is based on the recently published article Change is Coming: Plan S From the Early Career Scientist Perspective in HemaSphere by Dr Nuno Borges.
Host: Dr Christian Scharenberg; Guest: Dr Nuno Borges
This is the fourth of a series of podcasts discussing recently published scientific articles. More podcasts will be available in the future. Stay tuned!
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
What is clonal hematopoiesis of indeterminate potential (CHIP) and its associated risks in elderly patients?Join our guest Prof Kirsten Gronbaek and host Dr Christian Scharenberg as they discuss CHIP, its biological significance, frequency in the general population, and its association with epigenetic age.
Listen along as Prof Gronbaek dives deeper into the subject and explains the association and significance of CHIP with mutations and patient survival. Last but not least, Prof Gronbaek talks about the challenges and current landscape of trials and studies on treatment for CHIP.
This discussion is based on the recently published article Clonal Hematopoiesis and Epigenetic Age Acceleration in Elderly Danish Twins in HemaSphere by Professor Kirsten Gronbaek.
Host: Dr Christian Scharenberg; Guest: Professor Kirsten Gronbaek
This is the third of a series of podcasts discussing recently published scientific articles. More podcasts will be available in the future. Stay tuned!
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
What can a not-for-profit NGO do for patients in a time of war? Join our guests, Prof Konstanze Döhner, Prof Elizabeth Macintyre, and Dr Nathalie van Havre as they discuss what the European Hematology Association (EHA) has done in favor of Ukraine and the Ukrainian hematological community.
Our guests talk about support programs EHA has implemented and the obstacles that came with that. Prof Macintyre furthers the discussion by expressing her views on the role of medical organizations such as EHA in a crisis. This discussion is based on the recently published article How a Medical Association Can Make a Difference in a Crisis Situation in HemaSphere by Dr Nathalie van Havre.
This is the second of a series of podcasts discussing recently published scientific articles, more podcasts will be available in the future. Stay tuned!
Guests: Prof Konstanze Döhner, University Hospital of Ulm, Germany;
Prof Elizabeth Macintyre, Hôpital Necker-Enfants Malades et Université Paris Cité, France;
Dr Nathalie van Havre, EHA Executive Office, The Netherlands
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join our guest Prof David Rees and host Dr Christian Scharenberg as they discuss how the concept of precision medicine can be applied to Sickle Cell Disease (SCD). Listen as Prof David Rees talks about prognostic markers and how they can (or can't) guide SCD disease management, current and new treatment options for SCD patients, and how the situation of precision medicine can differ between low- and high-income countries. Last but not least, Prof David Rees ends the podcast with his view of how SCD management will be in the near and far future. This discussion is based on a recently published article, https://journals.lww.com/hemasphere/Fulltext/2022/09000/Precision_Medicine_and_Sickle_Cell_Disease.6.aspx (Precision Medicine and Sickle Cell Disease) by Prof David Rees, in https://journals.lww.com/hemasphere/pages/default.aspx (Hemasphere). This is the first of a series of podcasts discussing recently published articles. More podcasts in this series will be available in the future. Stay tuned! Visit the EHA Campus for more content on Hemoglobinopathies and Sickle Cell Disease: 1. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1106#/users/@self/catalogues/1700/programmes/310588/description (EHA Sickle cell disease program) 2. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1106#/users/@self/catalogues/1700/courses/400223/description (EHA Unplugged Sickle Cell Disease) podcast series (Available on all major podcast platforms and on the EHA Campus) 3. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1106#/users/@self/catalogues/1700/courses/435319/description (Gene Therapy in Hemoglobinopathies) Host: Dr Christian Scharenberg, Skaraborgs Hospital, Sweden; Guest: Professor David Rees, Kings College London, United Kingdom
What did you think of this podcast? Share your opinion with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
How did CLL lose its role of "Cinderella" in hematology in the last decades, thanks to the introduction of entirely new classes of drugs, and came under the spotlight of clinical research in hematology? Prof Jennifer Woyach discusses the fundamentals of CLL genetics and treatment in this podcast, as well as the selection of patients for therapy, the different, and somewhat unpredictable, clinical course the disease can follow, together with the last evidence from CLL clinical trials. Host: Prof Shaun McCann; Guest: Prof Jennifer Woyach What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
The links between thrombosis and cancer have been known for a long time and are associated with the type of cancer (pancreatic and lung carcinomas, for example, are particularly prone to give this complication), its localization, and the anti-neoplastic treatment used to fight the cancer itself. Prof Jan Marie Connors, in this podcast, explains how a thrombotic episode may represent the first indication of a cancer diagnosis, and how guidelines should be critically used to manage these patients, taking into account the concurrent anti-cancer therapy and potential drug interactions. Host: Prof Shaun McCann; Guest: Prof Jean Marie Connors What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In this podcast, Prof Tessa Andermann, an expert in infectious diseases, provides an overview of the role of the microbiome in the homeostasis of the human body and how it has been implicated in the development of complications after allogeneic transplantations, including acute graft-versus-host-disease, infections, mortality, and disease relapse. Some of the relationships observed between changes in the microbiome and clinical outcome might in the next future be better characterized and exploited to drive therapeutic choices. Host: Prof Shaun McCann; Guest: Prof Tessa Andermann What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
How do you make a diagnosis of erythrocytosis? Is full blood count enough or do you need more specific tests? How is the classification in primary and secondary erythrocytosis linked to EPO levels? Is idiopathic erythrocytosis really a vanishing entity? These are some of the questions Prof Mary-Frances McCullin answers in this podcast, giving listeners the key information necessary to understand erythrocytosis in clinical practice. Host: Prof Shaun McCann; Guest: Prof Mary-Frances McMullin What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the seventh and final episode of the Clinical Trial podcast series, you can hear Prof. Konstanze Döhner and Prof. Antonio Almeida exchanging ideas and thought-provoking opinions about how investigator-initiated clinical trials and new trial designs can provide patients early access to novel drugs. They discuss the importance of large collaborative groups, the complexity of current requirements that must be in place, and the impact that these challenges may have, along with the relevant issues that could be changed in order to enable more uncomplicated participation and conduction of clinical studies. In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map. It will help you answer interrogations such as: • What is a CRO? • How are clinical studies designed? • Which role(s) should sponsors fulfil? Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts. Host: Prof. Konstanze Döhner; Prof. Antonio Almeida What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
This series of two podcasts leads you on a journey through the main clinical and therapeutical aspects of Cutaneous T Cell Lymphomas (CTCLs), a heterogeneous group of lymphoid neoplasms characterized by primary cutaneous localization. Albeit rare, CTCLs have peculiar clinical characteristics, requiring a multidisciplinary approach and a strict collaboration between different specialists, allowing for a timely and precise diagnosis, critical for the good outcome of these patients. Join dermatologist Prof Maarten Vermeer (Dept. of Dermatology, Leiden University Medical Center) and hematologist Dr Erik Marijt (Head of the Central Laboratory of Clinical Hematology and the Interdivisional Flowcytometry Core Facility, Leiden University Medical Center) as they exchange their views and expertise on the diagnosis and management of patients with CTCLs. In this second episode, listen to Prof Vermeer and Dr Marijt discussing how CTCL patients with localized and diffuse disease can be effectively treated, and how new targeted agents and allogeneic transplantation can be integrated into the management algorithm. Hosts: Prof Maarten Vermeer; Dr Erik Marijt What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
This series of two podcasts leads you on a journey through the main clinical and therapeutical aspects of Cutaneous T Cell Lymphomas (CTCLs), a heterogeneous group of lymphoid neoplasms characterized by primary cutaneous localization. Albeit rare, CTCLs have peculiar clinical characteristics, requiring a multidisciplinary approach and a strict collaboration between different specialists, allowing for a timely and precise diagnosis, critical for the good outcome of these patients. Join dermatologist Prof Maarten Vermeer (Dept. of Dermatology, Leiden University Medical Center) and hematologist Dr Erik Marijt (Head of the Central Laboratory of Clinical Hematology and the Interdivisional Flowcytometry Core Facility, Leiden University Medical Center) as they exchange their views and expertise on the diagnosis and management of patients with CTCLs. In this first episode, listen to Prof Vermeer and Dr Marijt illustrating the dermatologic and hematologic approaches to the diagnosis and staging of CTCLs, including the different clinical presentation and prognosis of the most common types of CTCLs. Hosts: Prof Maarten Vermeer; Dr Erik Marijt What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
Dr David Kurtz discusses in this podcast the most recent technical developments and practical applications of circulating tumor DNA and liquid biopsies, an active area of research in the last 25 years, which is now gaining more importance and translational application in the clinic. In tumors like B-cell non-Hodgkin lymphomas, for example, somatic mutations can now be tracked and diagnosed using these techniques. Other fields of active investigations include CLL and solid tumors, as well as disease monitoring and early diagnosis on relapses. Host: Shaun McCann; Guest: Dr. David Kurtz What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
The whole world of CML changed in the early 2000s with the introduction of imatinib and TKIs, however, the situation in developing countries can be significantly different from Europe and USA, as discussed by Prof Hemant Malhotra in this podcast. Short-backs may encompass the molecular diagnosis and monitoring of the disease (not everywhere available) as well as the cost of drugs and medical expense coverage. On the other hand, the relative affordability of generic TKIs may cause skipping of expensive diagnostic procedures before starting treatment, whereas their current prolonged life expectancy is making the number of CML patients increasingly high. A complex picture that is worth listening to in order to better understand medicine across different regions in the world. Host: Shaun McCann; Guest: Prof. Hemant Malhotra
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
Transfusion processes have changed significantly in recent years, at the same time changing the guidelines for blood cell replacement therapy. Listen to Prof. Michael Murphy in this podcast as he provides an overview of the most up-to-date topics in transfusion, including the relevant risk of over-transfusion, restricted transfusion practices, and also the issues of delayed transfusion and transfusion-related infections. "Don't give two when one will do," should remain the bottom line criterion in transfusion decisions in stable patients. Host: Shaun McCann; Guest: Prof. Michael Murphy
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
This podcast follows a short discussion between two young hematologists on a clinical case review of a chronic myeloid leukemia patient called Naomi. In this discussion, the hematologists go through Naomi’s case while addressing the management of CML patients in complete molecular response and the requirements for discontinuation of tyrosine kinase treatment in CML patients. This podcast is rendered from QR Case 5 - Chronic Myeloid Leukemia (Naomi) on the EHA Campus. What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more podcasts or clinical cases? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the sixth episode of the Clinical Trial podcast series, Prof. Robert Hills discusses the different reasons that lead to the end of a trial – especially when it is earlier than planned. He also gives us a summary of what happens after the trial; the importance of some steps involving the data and their availability, and the writing of reports for the appropriate regulatory authorities. In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map. It will help you answer interrogations such as: • What is a CRO? • How are clinical studies designed? • Which role(s) should sponsors fulfil? Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts.
Host: Prof. Robert Hills
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the fourth episode of the EHA Diagnosing And Treating Iron Deficiency podcast series, host Prof Gunnar Birgegård and guest expert Prof Antonio Almeda discuss the diagnostic and therapeutic management of iron deficiency and anemia in the perioperative setting, a clinical situation where having inadequate iron stores carries significant clinical consequences on mortality and morbidity outcomes. They also address the conclusions of different studies that have investigated the impact of repleting patients with iron on the incidence of complications, mortality, or long-term health. They also disclose how they are monitoring their patients’ iron levels following surgery and why it is important. Host: Prof Gunnar Birgegård; Guest: Prof Antonio Almeda What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the EHA Diagnosing And Treating Iron Deficiency Program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the fifth episode of the Clinical Trial podcast series, Prof. Robert Hills discusses the documentation of clinical trials and how it represents a safeguard for the credibility of the trial. He points out the importance of finding a good balance between too many documents and not enough of them. In addition, he highlights the multitude of different groups working on a clinical trial, which ultimately renders documentation an insurance to a smooth process. In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map. It will help you answer interrogations such as: • What is a CRO? • How are clinical studies designed? • Which role(s) should sponsors fulfil? Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts.
Host: Prof. Robert Hills
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the fifth and final episode of the Aging Patient: Dispelling Myths podcast series, host Gareth Tucker and guest experts Prof Raul Cordoba, Dr Ulrich Wedding, and Dr Dominique Bron discuss the ethical issues associated with treating hematological malignancies in older adults. They raise different points regarding treatment decisions made with (and not without) the patient and amongst other parameters, how much of an impact costs have in the choice of treatment. Dr Bron also reminds us of the 4 principles of healthcare (nonmaleficence, beneficence, autonomy, and justice) – and that age is not a criterion in deciding whether a patient should be treated or not. Finally, they address the impact of COVID-19 on the current clinical practice and whether it has exacerbated ethical issues. Host: Gareth Tucker; Guest: Prof Raul Cordoba, Dr Ulrich Wedding, Prof Dominique Bron
In the second episode of the Aging Patient: Dispelling Myths podcast series, the importance of medical decision making based on a patient’s ‘fitness’ rather than their age will be stressed, and the impact of good diet and exercise in maintaining fitness and delaying sarcopenia highlighted.
Host: Gareth Tucker; Guest: Prof Alessandra Tucci, Prof Sergio Storti
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the Aging Patient: Dispelling Myths program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the fourth episode of the Clinical Trial podcasts, Dr. Eleftheria Hatzimichael gives us an overview of the sponsor's role and responsibilities in investigator-initiated clinical trials. The different meaning of "sponsor" and "funder", the importance for physicians to be involved in the design of clinical trials, the eight overarching responsibilities of the sponsor, are all key topics discussed in this podcast. In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map. It will help you answer interrogations such as: • What is a CRO? • How are clinical studies designed? • Which role(s) should sponsors fulfil? Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts.
Host: Dr. Eleftheria Hatzimichael
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the fourth episode of the Aging Patient: Dispelling Myths podcast series, host Gareth Tucker and guest expert Prof Monica Engelhardt discuss how comprehensive geriatric assessment can guide treatment decisions and improve patient outcomes. Dr Engelhardt gives us an insight into her clinical practice and how elderly hematology patients are receptive - or not - to this testing. You will also learn what are the parameters to consider when treating elderly patients for hematologic malignancies, e.g., how frailty can influence the outcomes of the treatment. Finally, Dr Engelhardt addresses the current pandemic situation regarding these patients: are older patients more vulnerable to COVID-19 when they are already suffering from hematological malignancies and under treatment? Host: Gareth Tucker; Guest: Prof Monika Engelhardt
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the Aging Patient: Dispelling Myths program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the third episode of the Clinical Trial podcasts, Prof. Martin Dreyling from the University of Munich makes several points about standards of care in clinical studies, also mentioned as GCPs (Good Clinical Practices). He gives us a historical perspective on the establishment of these standards 20 years ago, and how they need an update through what he calls a ‘reality check’. Prof. Dreyling is part of the coalition Reducing Bureaucracy in Clinical Trials and explains what they are proposing to update and improve GCPs in 2021. In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map. It will help you answer interrogations such as: • What is a CRO? • How are clinical studies designed? • Which role(s) should sponsors fulfil? Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts.
Host: Prof. Martin Dreyling
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the third episode of the Aging Patient: Dispelling Myths podcast series, host Gareth Tucker and experts Prof Antonio Almeida, Prof Valentin Goede, and Dr Annamaria Brioli discuss the treatment of hematological malignancies in older adults, involving polypharmacy in most cases. They describe how patients commonly react to polypharmacy and how challenging it can be to have all the information about a patient’s full list of medication, and to keep them compliant. They also address the step of deprescribing, a critical point in the therapy of these patients. Host: Gareth Tucker; Guest: Prof Valentin Goede, Prof Antonio Almeida, Dr Annamaria Brioli What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the Aging Patient: Dispelling Myths program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the second episode of the Clinical Trial podcasts, former EHA President Prof. John Gribben gives us an overview of the role(s) of CROs (Contract Research Organizations) in clinical investigation. He discusses how they can help, notably with the paper trails associated with clinical trials, and how they should be constructive partners in the process of clinical research. In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map. It will help you answer interrogations such as: • What is a CRO? • How are clinical studies designed? • Which role(s) should sponsors fulfil? Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts.
Host: Prof. John Gribben
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the second episode of the Aging Patient: Dispelling Myths podcast series, host Gareth Tucker discusses with experts Prof Alessandra Tucci and Prof Sergio Storti the definition and importance of patient assessment (including frailty, comorbidity, and polypharmacy), in older adults with hematological conditions and how it can be used to determine the overall ‘fitness’ of a patient. They also discuss the critical role of interactions between HCPs, patients, and their entourage in the assessment. You will listen to clinical examples showing how a complete geriatric assessment can help direct treatment for older patients with specific hematological malignancies and how a benefit can be obtained from more effective, novel treatments. Host: Gareth Tucker; Guest: Prof Alessandra Tucci, Prof Sergio Storti
Additional information (in order of mention): HCP: Healthcare Professional CLL: Chronic Lymphocytic Leukemia 11q minus: deletion of a portion of the long arm (q) of chromosome 11 SF3B1 gene: Splicing Factor 3B1 POT1 gene: Protection of Telomeres 1 AML: Acute myeloid leukemia IPSS: International Prognostic Scoring System ADL: Activities of Daily Living IADL: Instrumental Activities of Daily Living
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the Aging Patient: Dispelling Myths program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In this podcast, the last of a series dedicated to Multiple Myeloma in underserved patient populations with, Prof Sonja Zweegman focuses on the challenges associated with MM treatment in older patients, namely the assessment of frailty and how to adapt treatment in this population. The podcast also addresses the specific characteristics of MM in the elderly, including the incidence of genetic mutations and the role of comorbidities. Speaker: Prof Sonja Zweegman; Host: Prof Pieter Sonneveld What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1422#/users/@self/catalogues/355089/courses/392645/description (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/ (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the first episode of the Clinical Trial podcasts, Amsterdam UMC researcher and author of “A Quick Guide on How to Conduct Medical Research” Dr. Marieke Ter Wee points out the importance of formulating a research question at the beginning of any clinical trial. What models are used to formulate the question and answer to it? She unravels the main parts of a research proposal that should be elaborated by the authors of clinical studies. In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map. It will help you answer interrogations such as: • What is a CRO? • How are clinical studies designed? • Which role(s) should sponsors fulfil? Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts.
Host: Dr. Marieke ter Wee
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the Aging Patient: Dispelling Myths podcast series, Prof Raul Cordoba kicks off a series of podcasts that will offer you up-to-date information about hematology in older adults. For the first interview, he welcomes guest expert Dr Kristina Kirschner to discuss aging and clonal disease. You will learn how clonal hematopoiesis increases with advancing age and how the accumulation of some clonal mutations have been linked with hematological cancers. Dr Kirschner answers questions - asked by patients - about the definition of aging by hematologists, or the relation of aging and susceptibility to clonal cancers. They also address the mechanisms of epigenetic mutations in aging hematopoietic stem cells and the impact of genes drivers of myeloid malignancies in the elderly population.
Host: Dr Raul Cordoba; Guest: Dr Kristina Kirschner
Additional information (in order of mention): AML (disease): Acute Myeloid Leukemia MDS (disease): Myelodysplastic Syndromes DNMT3A gene (DNA Methyltransferase 3 Alpha) TET2 gene (Tet Methylcytosine Dioxygenase 2) ASXL1 gene (ASXL Transcriptional Regulator 1) CHIP (disease): (Clonal Hematopoiesis of Indeterminate Potential) PPM1D gene: Protein Phosphatase, Mg2+/Mn2+ Dependent 1D
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the Aging Patient: Dispelling Myths program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the third episode of the Iron Deficiency podcast series, host Prof Gunnar Birgegård and guest expert Dr Noemi Roy review the many important functions iron plays in the body, providing the background for the high prevalence of iron deficiency in women, particularly in their fertile life and during pregnancies. They address different strategies of treatment, including IV, oral treatment, and nutrition recommendations. Finally, they also highlight the importance of treating iron deficiency after childbirth when the mother comes back home. Host: Prof Gunnar Birgegård; Guest: Dr Noemi Roy What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the EHA Diagnosing And Treating Iron Deficiency Program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the second episode of the EHA Diagnosing And Treating Iron Deficiency podcast series, host Prof Gunnar Birgegård and guest expert Prof Christopher Winearls highlight the high prevalence of iron deficiency anemia in patients with CKD, together with its association with poor long-term outcomes. They discuss the importance of monitoring iron on top of monitoring erythropoietin and treating the deficiency prior to the use of erythropoietin. Overall, Prof Winearls discloses how to evaluate ferritin and Hb levels in CKD patients and how to treat iron deficiency and monitor outcomes in this special population. Host: Prof Gunnar Birgegård; Guest: Prof Christopher Winearls
Additional information (in order of mention): CKD (disease): Chronic Kidney Disease HIF PH (treatment): Hypoxia-Inducible Factor Prolyl Hydroxylase enzyme inhibitors
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the EHA Diagnosing And Treating Iron Deficiency Program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In the first episode of the EHA Diagnosing And Treating Iron Deficiency podcast series, Prof Gunnar Birgegård and host expert Prof Antonio Almeida define what is iron deficiency and more precisely functional iron deficiency. They discuss the prevalence of anemia in cardiac failure patients and the relation between severity of the heart disease and incidence of iron deficiency. They also highlight the importance of monitoring potential renal symptoms for better treatment outcomes. Host: Prof Gunnar Birgegård; Guest: Prof Antonio Almeida This episode was produced with the support of the World Heart Federation.
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the EHA Diagnosing And Treating Iron Deficiency Program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In episode 9 of "EHA Unplugged", Prof. Shaun McCann describes the importance of general medical management in multiple myeloma (MM) patients and the application of the principles of treatment in different subpopulations of patients. He also explains how to diagnose MM and assess the response to treatment. What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the course "EHA Unplugged - Hematological Diseases, HSCT and More". https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
This podcast, the second of a series dedicated to Multiple Myeloma in underserved populations, addresses clinical challenges in MM, with a focus on high-risk disease and cytogenetics. Prof Weisel describes the established genetic prognostic markers in MM, and the new abnormalities that are becoming important, besides the role and impact of Minimal Residual Disease (MRD) on risk status and classification of MM patients. Speaker: Prof Katja Weisel; Host: Prof Pieter Sonneveld
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1422#/users/@self/catalogues/355089/courses/392645/description (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/ (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In episode 8 of "EHA Unplugged", Prof. Shaun McCann details the diagnostic and prognostic criteria of CLL and the correct diagnostic work-up. He also describes the increasing array of treatments available for CLL patients and outlines the role of allogeneic transplantation in this disease. What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the course "EHA Unplugged - Hematological Diseases, HSCT and More". https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In episode 7 of "EHA Unplugged", Prof. Shaun McCann describes the clinical and genetic features of chronic myeloid leukemia (CML), discusses the best therapeutic options, and characterizes the changes that occur in the natural history of the disease after the introduction of tyrosine-kinase inhibitors (TKIs). What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the course "EHA Unplugged - Hematological Diseases, HSCT and More". https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
This podcast series brings together people affected by SCD and specialist hematologists to shed light on this widely misunderstood condition, bringing the guidelines to life and helping healthcare professionals improve their practice by understanding the patient experience. In this closing discussion, Dr Jo Howard and Professor Léon Tshilolo reflect on what they have learned from their conversations with people affected by sickle cell disease and sickle cell trait, and discuss the present and future of sickle cell disease treatment across the world.
SCD: What Physicians Can Learn From Patients And Carriers is a three-episode podcast series with the first one created to mark Black History Month 2021. It is a collaboration between EHA and Obsidian Healthcare Group, a global provider of medical education.
Interview with: Dr Jo Howard and Professor Léon Tshilolo Host: Mandi Watty-Miller
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to explore more podcasts or clinical cases? Please visit the EHA Campus. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe (https://eha.news/subscribe)
In this podcast, the first of a series dedicated to Multiple Myeloma in underserved patient populations, Prof Terpos illustrates the impact of renal disease on MM outcomes and how it should best be managed. Follow the podcast to learn about assessment and monitoring of renal function in MM patients, the available treatment options for this population, and the role and outcomes of kidney transplantation. Speaker: Prof Evangelos Terpos; Host: Prof Pieter Sonneveld
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1422#/users/@self/catalogues/355089/courses/392645/description (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/ (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
This podcast series brings together people affected by SCD and specialist hematologists to shed light on this widely misunderstood condition, bringing the guidelines to life and helping healthcare professionals improve their practice by understanding the patient experience. In the second episode, a mother and daughter affected by sickle cell are joined by hematologist Professor Léon Tshilolo for an interview with Mandi Watty-Miller, an individual with sickle cell trait. They discuss the experience of raising a child with sickle cell disease, navigating the world of online misinformation about the condition, and how to improve communication and trust between doctors and patients.
SCD: What Physicians Can Learn From Patients And Carriers is a three-episode podcast series with the first one created to mark Black History Month 2021. It is a collaboration between EHA and Obsidian Healthcare Group, a global provider of medical education.
Interview with: Prof Léon Tshilolo Host: Mandi Watty-Miller
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to podcasts? Please visit the EHA Campus and check out the EHA Unplugged catalog. https://ehacampus.ehaweb.org/
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, Dr. Rijneveld discusses BCR-ABL1-like acute lymphoblastic leukemia (ALL), a specific subgroup of ALL characterized by an expression profile similar to Ph+ ALL, albeit lacking the BCR-ABL1 rearrangement, and by sensitivity to TKIs. She highlights how TKIs were game-changing for the prognostic of these patients, although their cost and associated toxicities (usually low but fatiguing in the long-term), may still be issues in the clinical practice. Interview with: Anita Rijneveld. Host: Shaun McCann
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to podcasts? Please visit the EHA Campus and check out the EHA Unplugged catalog. https://ehacampus.ehaweb.org/
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen to this expert interview to discover characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults and children. Dr Advani guides us in the biology and genetics of the disease in these two categories of patients, dedicating a special focus to Philadelphia-like ALL and to the clinical and prognostic role of measurable residual disease (MRD). Finally, as CAR-T therapies are becoming available to adult ALL patients, challenges and promises of this approach are discussed in the concluding part of the podcast. Interview with: Anjali Advani. Host: Shaun McCann
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to podcasts? Please visit the EHA Campus and check out the EHA Unplugged catalog. https://ehacampus.ehaweb.org/
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, Dr Nemeth reminds us that iron is not only necessary for hematopoiesis and red cell production. A complex relationship exists between iron levels and susceptibility to infections, which involves the different sensibility of microbes to iron as well as the association between iron deficiency and poor response to immunization, as you will discover in this clear overview on the role of iron in host defence. Interview with: Elizabeta Nemeth. Host: Ayan Panjan What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to podcasts? Please visit the EHA Campus and check out the EHA Unplugged catalog. https://ehacampus.ehaweb.org/
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
This podcast series brings together people affected by SCD and specialist hematologists to shed light on this widely misunderstood condition, bringing the guidelines to life and helping healthcare professionals improve their practice by understanding the patient experience. In this first episode, consultant hematologist Dr Jo Howard has a conversation with two individuals affected by sickle cell disease (SCD) and sickle cell trait (SCT). They discuss the impact that the condition has on their personal and family lives, common misconceptions about the SCD experience, areas where treatment frequently falls short, and how to raise awareness further.
SCD: What Physicians Can Learn From Patients And Carriers is a three-episode podcast series with the first one created to mark Black History Month 2021. It is a collaboration between EHA and Obsidian Healthcare Group, a global provider of medical education.
Host: Dr Jo Howard
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to podcasts? Please visit the EHA Campus and check out the EHA Unplugged catalog. https://ehacampus.ehaweb.org/
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Listen to this podcast to hear a psychologist’s point of view on sickle cell disease (SCD), and how to address the psychological as well as the hematological needs of SCD patients. The importance of specific psychological support services for SCD patients, the concept of social stigmatization as a true complication of the disease, and its consequences for physicians dealing with these patients are discussed in this podcast. Interview with: Kofi Anie. Host: Ayan Panjan
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. The module associated with this podcast will be released on Oct 22. https://ehacampus.ehaweb.org/
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
This podcast focuses on the social aspects of SCD, in particular on the challenges confronting adolescents with SCD and their treating physicians. Prof. Hankins speaks about the delicate transition from pediatric to adult care, the use of technology in improving the care of these patients, and the issues associated with access to new treatments. Interview with: Jane Hankins. Host: Shaun McCann
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. The module associated with this podcast will be released on Oct 22. https://ehacampus.ehaweb.org/
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In this podcast, Dr Smith-Whitley illustrates the many different aspects and possible pregnancy complications for mother and fetus in women with SCD. Practical aspects dealt within the clinical practice, such as the management of pain in the pregnant woman, use of transfusions and HU, and reproductive education for SCD patients, are also discussed in the podcast. Interview with: Kim Smith-Whitley. Host: Shaun McCann
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. The module associated with this podcast will be released on Oct 22. https://ehacampus.ehaweb.org/
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
In episode 6 of "EHA Unplugged", Prof. Shaun McCann discusses Paroxysmal Nocturnal Hemoglobinuria. You will hear him describe the etiology and the clinical manifestations of paroxysmal nocturnal hemoglobinuria (PNH), apply the correct diagnostic work-up if the disease is suspected, and discuss the principles of treatment in these patients, including monoclonal antibodies and HCT.
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1422#/users/@self/catalogues/355089/courses/392645/description (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/ (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In episode 5 of "EHA Unplugged", Prof. Shaun McCann discusses HSCT in Severe Aplastic Anemia. You will hear him detail the diagnostic criteria of severe aplastic anemia (SAA) and the current therapeutic approaches for this disease. He will also characterize the results of HCT, the best conditioning options and different source of hemopoietic cells for SAA patients.
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1422#/users/@self/catalogues/355089/courses/392645/description (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/ (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In episode 4 of "EHA Unplugged", Prof. Shaun McCann discusses the phenomenon of engraftment and chimerism following hemopoietic cell transplantation (HCT) and the main techniques used to determine the origin of the cells in the recipient.
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1422#/users/@self/catalogues/355089/courses/392645/description (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/ (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In episode 3 of "EHA Unplugged", Prof. Shaun McCann talks about infections in HSCT.
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In episode 2 of "EHA Unplugged", Prof. Shaun McCann explains the relationship between HSCT and graft-versus-host disease. What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehaedu.org/Campus (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/ ) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook ) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/ ) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
In episode 1 of "EHA Unplugged", Prof. Shaun R McCann is describing the history of HSCT.
What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback)
Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions. https://ehacampus.ehaweb.org/ehailp/pages/description.jsf?menuId=1422#/users/@self/catalogues/355089/courses/392645/description (https://ehaedu.org/Campus)
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/ (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe (https://eha.news/subscribe)